CA2560798A1 - Administering pharmaceutical compositions to the mammalian central nervous system - Google Patents
Administering pharmaceutical compositions to the mammalian central nervous system Download PDFInfo
- Publication number
- CA2560798A1 CA2560798A1 CA 2560798 CA2560798A CA2560798A1 CA 2560798 A1 CA2560798 A1 CA 2560798A1 CA 2560798 CA2560798 CA 2560798 CA 2560798 A CA2560798 A CA 2560798A CA 2560798 A1 CA2560798 A1 CA 2560798A1
- Authority
- CA
- Canada
- Prior art keywords
- drug
- nervous system
- delivery
- olfactory
- agents
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Methods, compositions and systems are provided for the non-invasive transnasal and transocular drug delivery to the central nervous system using eriodictyon fluid extract technology. By administration through the olfactory nerve or the optical nerve, the delivery of a biologically active substance of interest into the CNS and CSF
can be enhanced through bypassing the blood-brain barrier. The invention involves the use of eriodictyon fluid extract as an excipient in compositions and systems for administering drugs to the olfactory or optical nerve.
can be enhanced through bypassing the blood-brain barrier. The invention involves the use of eriodictyon fluid extract as an excipient in compositions and systems for administering drugs to the olfactory or optical nerve.
Description
PATENT
Attorney Docket No.: 065193-5001-USO1 ADMINISTERING PHARMACEUTICAL COMPOSITIONS TO THE
MAMMALIAN CENTRAL NERVOUS SYSTEM
CROSS REFERENCE TO RELATED APPLICATION
[0001] This application is a continuation-in-part of U.S. Patent Application No. 111460,194, filed July 26, 2006, which claims priority to U.S. Provisional Patent Application No. 601720,797 filed on September 26, 2005, the disclosure of each of which is incorporated herein by reference in its entirety for all purposes.
BACKGROUND OF THE INVENTION
Attorney Docket No.: 065193-5001-USO1 ADMINISTERING PHARMACEUTICAL COMPOSITIONS TO THE
MAMMALIAN CENTRAL NERVOUS SYSTEM
CROSS REFERENCE TO RELATED APPLICATION
[0001] This application is a continuation-in-part of U.S. Patent Application No. 111460,194, filed July 26, 2006, which claims priority to U.S. Provisional Patent Application No. 601720,797 filed on September 26, 2005, the disclosure of each of which is incorporated herein by reference in its entirety for all purposes.
BACKGROUND OF THE INVENTION
[0002] It is well known to administer drugs to or through the skin or mucosa.
Such a mode of delivery provides many advantages; primarily, topical, tr~ansdermal or transmucosal delivery are generally comfortable, convenient and noninvasive ways of administering drugs.
The variable rates of absorption and metabolism encountered with oral treatment are avoided, and other inconveniences--gastrointestinal irritation and the; like--are eliminated as well.
Such a mode of delivery provides many advantages; primarily, topical, tr~ansdermal or transmucosal delivery are generally comfortable, convenient and noninvasive ways of administering drugs.
The variable rates of absorption and metabolism encountered with oral treatment are avoided, and other inconveniences--gastrointestinal irritation and the; like--are eliminated as well.
[0003) A number of problems have been encountered with the aforementioned modes of drug administration, however. The skin or mucosa can become irritated or sensitized by a particular drug, adhesive or skin permeation enhancer. Pain and itching may result and be serious enough that the patient may discontinue use of the dlrug. ;In addition, the skin may become dry or flaky upon continued administration of a particular pharmaceutical composition. If such problems persist and are severe enough in a large fraction of patients, a particular drug may simply be designated as unsuitable for administration to the skin or mucosa, even though therapeutically effective blood levels may have been achieved by administering the drug in this way.
[0004] The present invention is premised on the completely unexpected discovery that the oil extracted from the Yerba Santa plant (Eriodietyon californic:um; Eriodictyon glutinosum; also known as "eriodictyon fluid extract"; "consumptive's weed"; "bear's weed";
"mountain balm"' and "gum plant") is extremely effective as an excipient in compositions for application to the skin or mucosa, and minimizes or completely eliminates the irritation, sensitization and dryness which often accompanies topical, transdermal or transmucosal drug delivery.
'fhe novel excipient also makes possible the administration of a wider range of drugs than PATENT
previously believed possible, i.e., drugs which caused a significant degree of the aforementioned problems in a relatively large fraction of patients.
"mountain balm"' and "gum plant") is extremely effective as an excipient in compositions for application to the skin or mucosa, and minimizes or completely eliminates the irritation, sensitization and dryness which often accompanies topical, transdermal or transmucosal drug delivery.
'fhe novel excipient also makes possible the administration of a wider range of drugs than PATENT
previously believed possible, i.e., drugs which caused a significant degree of the aforementioned problems in a relatively large fraction of patients.
[0005] The Yerba Santa plant is an evergreen shrub indigenous to the hills and mountains of California and northern Mexico, and was long used by Indians for a number of purposes.
See, e.g., A. R. Hutchens, Indian Herbalogy of North America, Ontario: Merco, 19'75, at pp.
3I7-318. A number of references to the Yerba Santa plant teach its use as an expectorant (e.g., N. Coon, The Dictionary of Useful Plants, Emmaus, .Pa.: Rodale Press, 1974)), in treating colds, sore throats, catarrh, stomach aches, vomiting and diarrhea (see A. R.
Hutchens, supra), in treating hemorrhoids (D. G. Spoerke, :Herbal Medications, Santa Barbara, Cali~: Woodbridge Press, 1980, at p. 183), in treating diseases of the lung (Los Remedios de la Gente: A Compilation of Traditional New Mexican Hcrbal Medicines and Their Use, compiled by M. Moore, 1977}, and in masking t:he taste of quinine and other bitter medications (Spoerke, supra; see also G. E. Trease et al., Pharmacognosy, London: Cassell 8c Colber, 1978, at p. 463}). References related to the Yerba Manta plant, in addition to the Coon, Hutchens, Moore, Spoerke, and Trease et al. references cited in the preceding section, include V. J. Vogel, American Indian Medicine, The University of Oklahoma Press, 1970, at pp. 83, 399-400; W. H. Lewis et al., Medical Botany; Plants Affecting Man's Health, New York: John Wiley. & Sons, 1977, at p. 301; P. I-luson, Mastf~ring IIerbalism:
A Practical Guide, New York: Stein and Day, 1974, at p. 32; B. C. Harris, The Compleat Herbal, Barre, Mass.; Bane Publishers; 1972, at p. 197; N. Coon, Using Plants for Healing, Hcarthside Press, 1963, at p. 122; M. Grieve, A Modern Herbal, vol. 2 2, New York: Hafner publishing Co., 1969, at p. 865; and V. E. Tyler et al., Pharmacognosy, Philadelphia: Lee & Febiger, 1981, at p. 148:
[0006 Most of the efforts currently under way to discover new therapeutic drugs for disorders of the central nervous system (CNS) face the problem of delivering the drugs to the brain without impairing the activity or integrity of such substances or compounds, while minimizing systemic adverse effects. And that means finding a way around--or through--the blood brain barrier (BBB), the physiological barrier between bloodstream and brain.
[0007) Accordingly, it is a primary object of the present invention to address the above-identified need in the art, and to provide methods, compositions and drug delivery systems for transmucosal drug administration, specifically to the olfactory nerve, which involve the use of eriodictyon fluid extract as an excipient.
PATENT
[0008] The method provides an advantage by virtue of the intranasal administration of the medication to the olfactory nerve. The olfactory nerve provides a direct connection between the outside environment and the brain thus providing quick: and ready delivery of active agents for treatment of various disorders, however, delivery of drugs to the olfactory nerve must be approached with caution as the nasal mucosa in general and the olfactory neuroepithetium in particular are much more delicate and susceptible to damage than skin.
Furthermore, the olfactory neuroepithelium is a very specialized type of epithelium that has a limited surface area and a poor regeneration potential. Thus, formulations for delivery to the olfactory nerve must be minimally irritating. Furthermore, it is generally desired that the formulations deliver the drug in a highly effective manner, thereby minimizing the number of applications necessary and reducing the opportunities for irritation of the olfactory nerve.
[0009] The methods and compositions of the invention are based on the discovery that eriodictyon fluid extract is extremely effective in ameliorating the problems associated with delivery of drugs to the mucosa. Thus, formulations for dellivery of active agents to the olfactory nerve, which are formulated with eriodictyon fluid extract have unexpectedly beneficial properties, including being less irritating to the mucosa and more effectively delivering the active agent to the desired site due to the ability of the extract to adhere to the surface of the olfactory nerve.
[0010] In one aspect of the invention, a system is provided for delivering a drug to the olfactory nerve, the system comprising:
(a) a source of the drug to be administered;
(b) a source of an excipient composition comprising eriodictyon fluid extract;
and (c) a pressurized delivery device, configured to deliver the drug and excipient to the olfactory nerve.
[0011] In another aspect, the invention encompasses pharmaceutical compositions containing a drug and the eriodictyon-based excipient. These compositions may be simply a mixture of drug and eriodictyon fluid extract, wherein the eriodictyon fluid extract serves as an excipient, or they may be mixtures of drug, eriodictyon-based excipient, and one or more vehicles, carriers, diluents, permeation enhancers, or the like. The composition may be in the form of a solution, suspension, ointment, gel, cream, etc.
(0012] In still another aspect, the invention is directed to a method of facilitating adherence of an agent to the olfactory nerve, the method involving appl'.ying the agent to the olfactory nexve in conjunction with an excipient composition containing eriodictyon fluid extract. This aspect of the invention is based on the discovery that eriodictyon fluid extract is useful as a PATENT
bioadhesive, i.e., a species which will increase adhesion olFa device (e.g., a transdermal drug delivery device) or chemical species (such as a drug in an ointment, gel, solution or suspension) to the skin or mucosal tissue. In related aspects, other methods of using compositions containing eriodictyon fluid extract are provided.
[0013] Additional objects, aspects and advantages of the present invention axe set forth in the detailed description that follows.
[0014] FIG. 1, comprising F1GS.1A to 1B, sets forth an exemplary bag on valve delivery system of use in the present invention.
DETAILED DESCRIPTION OF THIS INVENTION
[0015] Before describing the present compositions, systems and methods of the invention in detail, it is to be understood that this invention is not linvted to the particular drugs, delivery systems, or dosage regimens described herein as such may, of course, vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to be limiting since the scope of the present invention will be limited only by the appended claims.
10016] It must be noted that, as used in this specification and the appended claims, the singular forms "a," "an" and "the" include plural referents unless the context clearly dictates otherwise. Thus, for example, reference to a. laminated structure containing "a drug" includes a mixture of two or more drugs, reference to "an adhesive" includes reference to one or more of such adhesives, and reference to "a solvent" includes reference to a mixture of two or more solvents. ' [0017] Other definitions of words and phrases used throughout this specification and the appended claims are as follows.
[0018] The term "drug" as used herein is intended to mean a compound or composition of matter which, when administered to an organism (human or animal) induces a desired pharmacologie and/or physiologic effect by local andlor systemic action. In general, the terms include the therapeutic or prophylactic agents in all major tlaerapeutic/prophylactic areas of medicine. Examples of drugs useful in conjunction with the: present invention include: anti-infectives such as antibiotics and antiviral agents; analgesics and analgesic combinations;
anorexics; anticholinergic agents; anticonvulsants; antidepressants;
antidiabetic agents;
antihistamines; anti-inflammatory agents, antimigraine preparations; anti-motion sickness PATENT
drugs; antinauseants; antineoplastics; antiparkinsonism drugs; antipruritics;
antipsychotics;
antipyretics; antispasmodics; sympathomimetics; xanthine derivatives;
cardiovascular preparations including calcium channel blockers and beta-blockers such as pindolol and antiarrhythmics; antihypertensives; diuretics; vasodilators including general coronary, peripheral and cerebral; central nervous system stimulants; cough and cold preparations, including decongestants; steroids; hypnotics; immunosuppressives; muscle relaxants;
parasympatholytics; psychostimulants; sedatives; tranquilizers; and agents for alleviating drug withdrawal symptoms.
[0019] The term "effective amount" as used herein intends that quantity of material which, when used or administered to a patient as indicated, is sufficient to provide the desired or intended beneficial effect. An "effective amount" of eriodictyon fluid extract to alleviate chemically induced irritation, e.g., irritation resulting from~topical, transdermal or transmucosal administration of a drug, is an amount which is sufficient to provide a desired degree of relief. Again, the "effective amount" in this latter case will vary with the individual, the degree of irritation, and possibly with the particular type of chemical or drug, if any, which is inducing the irritation.
[0020] By "eriodictyon fluid extract" or "Yerba Santa fluid extract" as used herein is meant the fluid which may be extracted from dried Yerba Santa leaves. One exemplary method for obtaining this Yerba Santa fluid extract is set forth in Remi:ngton's Pharmaceutical Sciences, 17th Ed., 1985, at pp. 128b and 1516, which is incorporated herein by reference to disclose such an extraction method. As described in detail in the aforementioned reference, the dried Yerba Santa plant is preferably processed in alcohol and water, followed by straining, pressing and clarification by, for example, decantation or filtration.
[0021] "Carriers" or "vehicles" as used herein refer to carrier materials suitable for transdermal, transmucosal or topical drug administration, and include any such materials known in the art, e.g., any liquid, gel, solvent, liquid diluenl;, solubilizer, or the like, which is nontoxic and which does not interact with other component's of the particular composition or system in a deleterious manner. Examples of suitable carriers for use herein include water, mineral oil, silicone, nontoxic organic solvents, petroleum jelly, and a variety of other materials. The particular carrier or vehicle selected will depend on the particular system used, the desired rate of drug administration, as well as on the particular drug and its solubility in various solvents.
[0022] "Permeation-enhancement agent" refers to excipients in a composition for intranasal drug administration that enhance overall delivery, dose consistency andlor pharmaceutical PATENT
acceptance. The methods for assessing enhancement are duantitative and are defined in the examples herein. Functional in vitro cell-based testing and methods are used to compare the effects of drug molecule by itself versus the same mass of drug molecule formulated and administered with excipients. "Enhancement" is a rnultiva.riant value proposition encompassing total bioavailability, net uptake, consistency of uptake and dosing, drug metabolism, degradation during dosing, drug targeting to active site(s), mucosal irritation, and overall safety and toxicity. In some cases, the relative benefit of the drug is used to optimize the excipient composition of the formulation, even at the expense of factors such as comfort and side effects. As explained when "pharmaceutical acceptance" was defined, the benefits of therapy may outweigh the discomfort of delivery. Chronic administration must also be considered. However, comfort and safety are optinnized when overall delivery is not unacceptably compromised. As an illustration of the balance, pH may improve the stability of a drug and its transmucosal flux, but a formulation pH outside the range of pH 3 to 8.5 may result in pain and tissue damage when administered nasally.
Introduction [0023] It has long been known that the bulk of the brain and the spinal cord is surrounded by a specially secreted clear fluid called the cerebrospinal fluid (CSF).
Chemical substances such as metabolites move relatively freely from the alimentary canal into the blood, but not into the CSF. As a result, the blood levels of sugars, amino acids or fatty acids fluctuate ovex wide range while their concentrations in the CSF remain relatively stable. The same is true for hormones, antibodies, certain electrolytes, and a variety of drugs.
Injected directly into the blood, they act rapidly on peripheral tissues such as the muscles, heart, or glands but they have little or no effect on the central nervous system (CNS).
[0024] When administered into the CSF, however, the same substances exert a prompt and strong action. The conclusion is that the substances injected into the blood do not reach the CSF and the brain with sufficient rapidity and in an effective concentration.
[0025] 'the way in which the brain keeps its environment constant is frequently discussed in terms of a blood-brain barrier (BBB). Once substances have found their way into the CSF, they are free to diffuse into the tissues of the brain. The entry of hydrophilic and relatively large molecules into the CNS is restricted by the existence of a BBB. The BBB
separates the brain from the blood circulation and is involved in the homeostasis of the brain. The BBB is situated in the brain microvessels and is composed of various cell types like endothelial cells, PATENT
astrocytes, microglial cells, perivascular macrophages, and pericytes. The cerebral and endothelial cells form the morphological and functional basis of the BBB.
j0026] The olfactory area is located high in the nasal vault above the superior turbinate.
Sensory hairs extend from the surface of the olfactory area to the cells that lie deep in the mucosa. Nerve fibers subserving the sense of smell have tlneir cells of origin in the mucous membrane of the upper and posterior parts of the nasal cavity. The entire olfactory mucosa covers an area of about 2.5 cm2. The central processes of olfactory fila are very fine urunyelinated fibers that converge to form small fascicles enwrapped by Schwann cells and pass through openings in the cribriform plate of the ethmoid bone into the olfactory bulb.
The axons of the mitral and tufted enter the olfactory tract, which courses along the olfactory groove of the cribriform plate to the cerebrum. Some fibers project to the medial dorsal nucleus of the thalamus and the hypothalamus. That olfactory stimuli and emotional stimuli are strongly linked is not surprising, in view of their common roots in the limbic system.
(0027] According to Belt, the olfactory system has direct rneuroanatomical and neurophysiological input to the amygdala and eventually hippocampus. Therefore it is conceivable that chemical stimuli at low levels could trigger limbic dysfunction in patients who happen to meet descriptive criteria for somatization disorder. It is also stated that there is no blood-brain barrier in the nasal passages. The limbic structure (e.g.
the amygdala, olfactory bulb and hippocampus) can become easily kindled. The olfactory nerves can transport toxins directly to the limbic system. This may result in symptoms including .
memory loss, irritable bowel, and migraine headaches.
[0028) It has been suggested by Shipley, that it is possible to transport substances which come into contact with the nasal epithelium to the brain and that it is thus possible to ' influence the function of neurons in the brain, including some which have extensive projection to wide areas of the CNS.
[0029] The optic nerve, mediating vision, is distributed to the eyeball. Most of its fibers are afferent and originate in the nerve cells of the ganglionic layer of the retina.
Developmentally, the optic nerves and the retinae are parts of the brain and their fibers with glia.
(0030] The optic nerve, about 4 cm long, is directed backwards and medially through the posterior part of the orbital cavity. It then runs through the optic canal into cranial cavity and joins the optic chiasma. The optic nerve is enclosed in three sheaths, which are continuous with the membranes of the brain, and are prolonged as far as the back of the eyeball.
Therefore, lhcrc is a direct connection between the optic nerve and the brain structures.
PATENT
[0031] Itaya and van Hoesen described transneuronal retrograde labeling of neurons in the stratum griseum superficiale ofthe superior colliculus following intraoeular injection of wheat germ agglutinin-horseradish peroxidase. A study of the distribution of wheat germ agglutinin-horseradish peroxidase in the visual system following intraocular injections in the chick, rat and monkey confirmed early findings of transneiual transport of this conjugate in vivo.
[0032) From the overview of the literature given above we can conclude the following.
Many substances such as metabolic products, drugs, and other substances cannot or only to a limited extent cross the BBB from the blood into the brain. From the nasal cavity these substances can penetrate into the brain because in the area of 2.5 cm2 of the upper posterior part of the nasal cavity, the BBB does not exist. Therefore., substances introduced into the upper part of the nasal cavity can directly enter the brain. Access to the CNS
is also possible through the optic nerve.
THE EMBODIMENTS.
[0033] In one aspect of the invention, a system is provided for delivering a drug to the olfactory nerve, the system comprising:
(a} a source of the drug to be administered;
(b) a source of an excipient composition comprising eriodictyon fluid extract;
and (e) a pressurized delivery device, configured to deliver the drug and excipient to the olfactory nerve.
[0034] In an exemplary embodiment, the pressurized device is a bag on valve device such as that illustrated in FIG. lA. The device includes an optionally detachable delivery nozzle or head, which is configured to deliver the drug and excipient to the olfactory nerve (FIG. 1B}.
In operation, the nozzle is inserted into the nasal cavity to the proper depth and a charge of the dxug/excipient composition is administered within the nasal cavity, traveling to at least the upper third of the nasal cavity where an amount of the drug effective to achieve a desired result is absorbed through the olfactory nerve into the CNS.
[0035] An exemplary nozzle of use in the system of the invention, and in practicing the invention has a length insertable into the nasal cavity of from about 1 cm to about 3 cm.
[0036] The method of the invention delivers the agent to the nasal cavity of a mammal. It is preferred that the agent be delivered to the olfactory area in the upper third of the nasal cavity and particularly to the olfactory epithelium in order to promote transport of the agent into the peripheral olfactory neurons rather than the capillaries within the respiratory epithelium. The PATENT
invention prefers the transport of agents to the brain by means of the nervous system instead of the circulatory system so that potentially therapeutic agents that are unable to cross the blood-brain barrier from the bloodstream into the brain may be delivered to the brain.
[0037] In a particularly preferred embodiment, the amount of drug absorbed through the olfactory nerve from a formulation of the instant invention is greater than the amount absorbed through this nerve from a formulation that does not include the erlodictyon extract.
More preferably, the amount of drug absorbed by the olfactory nerve from a formulation of the instant invention per unit time is greater than that absorbed from a formulation that does not include the eriodictyon extract. Still other preferred embodiments result in a lower frequency or a lesser degree of irritation of the nasal cavity and/or olfactory nerve upon administration of a formulation of the invention when compared to an analogous formulation that does not include the eriodictyon extract.
[0038] It is preferred that the agent is capable of at least partially dissolving in the fluids that are secreted by the mucous membrane that surround the cilia of the olfactory receptor cells of the olfactory epithelium in order to be absorbed into the olfactory neurons.
Alternatively, the invention may combine the agent with a carrier and/or other substances that faster dissolution of the agent within nasal secretions. Useful adjuvants include lipids, e.g., GM-1, phosphatidylserine (PS), and emulsifiers such as polysorbate 80.
[0039] To further facilitate the transport of the agent into the olfactory system, the method of the present invention combines the agent with a substance, e.g., er~iodictyon extract, that enhances the residence time of the agent in contact with the olfactory epithelium, thereby enhancing absorption of the agent through the olfactory epithelium. It is generally preferred that the additives promote the retention of the agent in contrct with the peripheral olfactory receptor cells. These peripheral neurons provide a direct connection between the brain and the outside environment due to their role in odor detection.
(0040] If the inherent permeability of mucosal tissue to some drugs (e.g., steroids) is too low to permit therapeutic levels of drugs to pass through a reasonably sized area of unbroken mucosa, a permeation enhancer can be administered with such drugs.
Accordingly, in such cases, the enhancer will be present in the drug/excipient formulation.
[0041] Thus, in another exemplary embodiment, the agent includes a permeation-enhancing agent that increases permeation of the drug into the olfactory nerve.
Permeation-enhancing agents are selected from the groups consisting of bile acids, bile salts, ionic, nonionic zwitterionic, anionic, cationic, gemini pair surfactants, phos~pholipids, alcohols, glycyrrhetinic acid and its derivatives, enamines, salicylic acid and sodium salicylate, acetoaeetate glycerol PATENT
esters, dimethylsulfoxide, n-methylpyrrolinidinone, cycloalextrins, medium chain fatty acids, short chain fatty acids, short and medium chain diglycerides, short and medium chain monoglycerides, short chain triglycerides, calcium chelato:rs, amino acids, cationic amino acids, homopolymerie peptides, cationic peptides, n-acetylamino acids and their salts, degradative enzymes, fatty acid synthesis inhibitors, cholesterol synthesis inhibitors.
[0042] Permeation enhancers are screened on a case-by-case basis to determine the most suitable candidate. Various models have been studied, for example those of LeCluyse and Sutton (1997. "In vitro models for selection of development candidates.
Permeability studies to define mechanisms of permeation enhancement" Advanced Drug Delivery Reviews, 23:163-I 83). In vztro methods with the EpiAirway model lhave proven to be valuable.
[0043] It is preferred chat the permeation-enhancing agent is lipophilic in order to promote absorption into the olfactory neurons and through the olfactory epithelium.
Among; those permeation-enhancing agents that are lipophilic are lipids, n.g., gangliosides and phosphatidylserine (PS). Uptake ofnon-lipophilic agents, e.g., nerve growth factor (NGF), may be enhanced by the combination with a lipophilic subsaance.
[0044] In one embodiment of the method of the invention, the drug may be combined with micelles comprised of lipophilic substances. Such micelles may modify the permeability of the nasal membrane and enhance absorption of the agent. Among the Iipophilic micelles that are preferred are gangliosides, particularly GM-1 ganglioside, and phosphatidylserine (PS).
The neurologie agent may be combined with one or several types of micelle substances.
[0045] Once the drug has crossed the olfactory epithelium, the invention further provides for transport of the neurologic agent along the olfactory neural pathway and generally into the CNS. The agent itself may be capable of movement within the olfactory system.
In particular, neurotrophic and neuritogenic substances have demonstrated ready incorporation into nerve cell membranes and an affinity for nerve cell receptor sites.
Indications are that these substances are naturally synthesized in tissues in response to neural stimulation and that they subsequently bind to receptors on neurons where they act as nerve growth promoting factors.
[0046] An exemplary drug delivery system of the invention contain a source of drug, a source of a pharmaceutically acceptable excipient composition containing eriodictyon fluid extract. Generally, the system is configured to deliver both the selected drug and the:
eriodictyon fluid to the desired area. The system also provides a means for propelling the agent and extract through the nasal cavity a sufficient distance to bring the agent and extract into operative contact with the olfactory nerve.
PATENT
[0047] The drug/excipient composition contained within the device and delivered therefrom to the olfactory nerve may take a number of forms. The drug and extract may be delivered "neat;' i.e., in the absence of additional liquid. Alternatively, the drug and extract may be dissolved, dispersed or suspended in a suitable pharmaceutically acceptable solvent. The excipient composition contains eriodictyon fluid extract as its active ingredient, and may or may not contain any additional components. Typically, the excipient composition will be eriodictyon fluid extxact itself. In some cases, however, other carriers or vehicles as described above may be incorporated into the excipient composition as well. Still other components can be incorporated into the excipient composition, including preservatives, stabilisers, surfactants, coloring agents, and the like. The drug/excipient composition in the reservoir will typically contain on the order of 0.1 to 20.0 wt. %, more preferably about 0.1 to 10.0 wt.
%, most preferably about 0.5 to 5.0 wt. %, eriodictyon fluid extract (i.e., relative to the total drug/excipient composition), with the amount of drug dependent on a variety of factors, including the desired rate of delivery, the desired dosage, the disease to be treated, the nature and activity of the drug, the desired effect, possible adverse reactions, the ability and speed of the agent selected to reach its intended target, and other factors within the particular knowledge of the patient and the physician.
[0048] The eriodictyon fluid extract itself is an excellent source of antioxidants and can serve as a preservative for oxidation-sensitive drug substances (Liu, J, Nat. Prod.
55: 357-363 (1992); Arriaga-Giner, Z. Naturforsch. 43: 5-6 (1988)). Moreover, the role of reactive oxygen species (ROS) in various disease states is well-recognized. Thus, even in.the absence of a drug, delivery of the anti-oxidants of the eriodictyon fluid extract to the CNS through the olfactory nerve provides a modality for treating and preventing a condition in which .
oxidation, e.g., by ROS, is implicated. Thus, the present invention also provides methods and systems for the delivery of anti-oxidants to the CNS by delivery of a composition containing these anti-oxidants to the olfactory nerve. Exemplary anti-oxidants are those typically found in eriodictyon fluid extract, e.g., flavoncs.
[0049] In still another preferred embodiment, the composition has anti-cancer chemotherapeutic properties. The properties can be derived from species present in the eriodictyon fluid extract, or they can be added to the extract.
[0050] As noted above, a wide variety of drugs (active agents) can be used in conjunction with the compositions and devices of the present invention. Preferred drugs within the classes identified earlier herein include but are not limited to~ the following: analgesics such as aspirin, ibuprofen and acetaminophen; opiates such as morphine; antibiotics such as PATENT
sulfacetamide, clindamycin and erythromycin; anticholinergic agents such as scopolamine;
antidiabetic agents such as insulin; antifungal agents such as nystatin and amphotericin B;
antiviral agents such as amantadine and acyclovir; antihistamines such as diphenhydramine;
antinauseants such as meclozine; antineoplastic agents such as fluorouracil and methotrexate;
antipsychotics such as prochlorperazine; steroids such as hydrocortisone, progesterone, and estrogens, therapeutic peptides such as growth factors, antibodies, insulin;
and compositions for treating drug withdrawal containing, e.g., a CNS stimullant such as caffeine and a serotonin antagonist such as dihydroergotamine or a salt thereof (such compositions are described in applicant's co-pending, commonly assigned U.S. patent application Ser. No.
07/500,034, filed 27 Mar. 1990, now U.S. Pat. No. 5,051,426, and entitled "Method and Compositions for Effecting Withdrawal from Drug Dependency", the disclosure of which is incorporated by reference herein).
[0051] Suitable active agents include, but are not limited tc>, psychopharmacological agents, such as (1) central nervous system depressants, e.g., general anesthetics (barbiturates, benzodiazepines, steroids, cyclohexanone derivatives, and miscellaneous agents), sedative-hypnotics (benzodiazepines, barbiturates, piperidinediones and triones, quinazoline derivatives, carbamates, aldehydes and derivatives, amides, acyclic ureides, benzazepines and related drugs, phenothiazines, etc.), central voluntary muscle tone modifying drugs (anticonvulsants, such as hydantoins, barbiturates, oxazolidinediones, succinimides, acylureides, glutarimides, benzodiazepines, secondary and tertiary alcohols, dibenzazepine derivatives, valproic acid and derivatives, GABA analogs, etc.), analgesics (morphine and derivatives, oripavine derivatives, morphinan derivatives, phenylpiperidines, 2,6-methane-3-benzazocaine derivatives, diphenylpropylamines and isosteres, salicylates, p-aminophenol derivatives, 5-pyrazolone derivatives, arylacetic acid derivatives, fenamates and isosteres, ete.) and antiemetics (antictiolinergics, antihistamines, antidlopaminergics, ete.), (2) central nervous system stimulants, e.g., analeptics (respiratory stimulants, eonvulsant stimulants, psychomotor stimulants), narcotic antagonists (morphine derivatives, oripavine derivatives, 2,6-methane-3-benzoxacine derivatives, morphinan derivatives) nootropics, {3) psychopharmacologicals, e.g., anxiolytie sedatives (benzodiazepines, propanediol carbamates) antipsychotics (phenothiazine derivatives, thio~;anthine derivatives, othE~r tricyclic compounds, butyrophenone derivatives and isoster~;s, diphenylbutylamine derivatives, substituted benzamides, arylpiperazine derivatives, indole derivatives, etc.), antidepressants (tricyclic compounds, MAO inhibitors, etc.)" pharmacodynamic agents, such as (1) peripheral nervous system drugs, e.g., local anesthetics (ester derivatives, amide PATENT
derivatives), (2) drugs acting at synaptic or neuroeffector functional sites, e.g., cholinergic agents, cholinergic blocking agents, neuromuscular blocking agents, adrenergic agents, antiadrenergic agents, {3) smooth muscle active drugs, e.g., spasmolytics (anticholinergics, musculotropic spasmolytics), vasodilators, smooth muscle stimulants, (4) histamines and antihistamines, e.g., histamine and derivative thereof (betazole), antihistamines (H,-antagonists, H2-antagonists), histamine metabolism drugs, chemotherapeutic agents, such as (1) anti-infective agents, e.g., ectoparasiticides (chlorinated hydrocarbons, pyrethins, sulfurated compounds), anthelminties, antiprotozoal agents, antimalarial agents, antiamebic agents, antileiscmanial drugs, antitrichomonal agents, antitrypanosomal agents, sulfonamides, antimycobacterial drugs, antiviral ehemotherapeutics, etc., and (2) cytostatics, i.e., antineoplastic agents or cytotoxic drugs, such as alkylating agents, e.g., Mechlorethamine hydrochloride (Nitrogen Mustard, Mustargen, ~-IN2), Cyclophospharnide {Cytovan, Endoxana), Ifosfamide (1FEX), Chlorambucil (Leukeran), Melphalan (Phenylalanine Mustard, L-sarcolysin, Alkeran, L-PAM), Busulfan {Myleran), Thiotepa (Triethylenethiophosphoramide), Carmustine (BiCNU,13CNU), Lomustine (CeeNU, CCNU), Streptozocin (Zanosar) and the like; plant alkaloids, e.g., Vincristine (Oncovin), Vinblastine (Velban, Velbe), Paclitaxel (Taxol), and the like; antimetab~olites, e.g., Methotrexate (MTX), Mercaptopurine (Purinethol, 6-MP), Thioguanine.(6-TG), Fluorouracil {5-FL1), Cytarabine (Cytosar-U, Ara-C), Azacitidine (Mylosar, 5-AZA) and the like; antibiotics, e.g., Dactinomycin (Aetinomyein D, Cosmegen), Doxorubic-in (Adriamyein), Daunorubiein (duanomycin, Cerubidine), Idarubicin (Idamycin), Bleomycin (Blenoxane), Picamycin (Mithramycin, Mithracin), Mitomycin {Mutamycin) and the like, and other anticellular proliferative agents, e.g., Hydroxyurea (Hydrea), Procarbazine (Mutalane), Dacarbazine (DTTC-Dome), Cisplatin (Platinol) Carboplatiri (Paraplatin), Asparaginase (Elspar) Etoposide (VePesid, VP-16-213}, Amsarcrine (AMSA, m-AMSA), M:itotane (Lysodren), Mitoxantrone (Novatrone), and the like. Chemotherapeutic agents may be those which are for treatment of a disease or disorder in the brain or central nervous system of the patient but demonstrate unacceptable systemic toxicity at desired doses. The general systemic toxicity associated with therapeutic levels of such agents may be reduced by their adlministration via the olfactory and/or optical nerves. Contemplated as examples are cardiotoxic compounds that are useful therapeutics but are dose limited by cardiotoxicity [0052] Suitable active agents include, but are not limited to: Antibiotics, such as:
aminoglycosides, e.g., amikacin, apramycin, arbekacin, bambermycins, butirosin, dibekacin, PATENT
dihydrostreptomycin, fortimicin, gentamicin, isepamicin, lcanamycin, micronomcin, neomycin, netilmicin, paromycin, ribostamycin, sisomicin, spectinomycin, streptomycin, tobramycin, trospectomycin; amphenicols, e.g., azidamfen.icol, chloramphenicol, florfenicol, and theimaphenicol; ansamycins, e.g., rifamide, rifampin, rifamycin, rifapentine, rifaximin;
beta.-lactams, e.g., carbacephems, carbapenems, cephalosporins, cehpamycins, monobactams, oxaphems, penieillins; lineosamides, e.g., clinamycin, lineomycin; macrolides, e.g., clarithromycin, dirthromyein, erythromycin, ete.; polypeptides, e.g., amphomycin, bacitracin, capreomycin, etc.; tetracyclines, e.g., apieycline, chlortetracycline, clomocycline, etc.; synthetic antibacterial agents, such as 2,4-diaminopyrimidines, nitrofurans, guinolones and analogs thereof, sulfonamides, sulfones;
[0053] Suitable active agents include, but are not limited to: Antimalarials, such as:
acedapsone, amodiaquin, arteether, artemether, artemisinin, artesunate, atovaquone, bebeerine, berberine, chirata, chlorguanide, chloroquine, chlorprogaunil, cinchona, cinchonidine, cinchonine, cycloguanil, gentiopicrin, halofantrine, hydroxychloroquine, mefloquine hydrochloride, 3-methylarsacetin, pamaquine, plasmocid, primaquine, pyrimethamine, quinacrine, quinidine, quinine, quinocide, quinoline, dibasic sodium arsenate;
[0054]Suitable active agents include, but are not limited to: Antiprotozoan agents, such as:
acranil, tinidazole, ipronidazole, ethylstibamine, pentamidine, acetarsone, aminitrozole, anisomycin, rufuratel, tinidazole, benzidazole, suramin, andl the like.
[0055] Suitable drugs for use as active agents are also listed in: Goodman &
Gilman's, The Pharmacological Basis of Therapeutics (9th Ed) (Goodman et al. eds) (McGraw-Hill) ( t 996);
and 2006 Physician's Desk Reference.
[0056] Suitable active agents include, but are not limited to: antineoplastic agents, as disclosed in U.S. Pat. Nos. 5,880,161, 5,877,206, 5,786,344., 5,760,041, 5,753,668, 5,698,529, 5,684,004, 5,665,7I5, 5,654,484, 5,624,924, 5,61.8,813, 5,610,292, 5,597,831, 5,530,026, 5,525,633, 5,525,606, 5,512,678, 5,508,277, S,4fi3,181, 5,409,893, 5,358,952, 5,318,965, 5,223,503, 5,214,068, 5,196,424, 5,109,024, 5,106,996, 5,101,072, 5,077,404, 5,071,848, 5,066,493, 5,019,390, 4,996,229, 4,996,206, 4,970,318, 4,968,800, 4,962,114, 4,927,828, 4,892,887, 4,889,859, 4,886,790, 4,882,334, 4,882,333, 4,871,746, 4,863,955, 4,849,563, 4,845,216, 4,833,145, 4,$24,955, 4,785,085, 4,684,747, 4,618,685, 4,611,066, PATENT
4,550,187, 4,550,186, 4,544,501, 4,541,956, 4,532,327, 4,490,540, 4,399,283, 4,391,982, 4,3$3,994, 4,294,763, 4,283,394, 4,246,411, 4,214,089, 4,150,231, 4,147,798, 4,056,673, 4,029,661, 4,012,448; psychopharmacological/psychot- ropic agents, as disclosed in U.S. Pat.
Nos. 5,192,799, 5,036,070, 4,778,800, 4,753,951, 4,590,180, 4,690,930, 4,645,773;, 4,427,694, 4,424,202, 4,440,781, 5,686,482, 5,478,828, 5,461,062, 5,387,593, 5,387,586, 5,256,664, 5,192,799, 5,120,733, 5,036,070, 4,977,167, 4,904,663, 4,788,188, 4,778,800, 4,753,951, 4,690,930, 4,645,773, 4,631,285, 4,617,314, 4,E>13,600, 4,590,180, 4,560,684, 4,548,938, 4,529,727, 4,459,306, 4,443,451, 4,440,781, 4,427,694, 4,424,202, 4,397,853, 4,358,451, 4,324,787, 4,314,081, 4,313,896, 4,294,828, 4,277,476, 4,267,328, 4,264,499, 4,231,930, 4,194,009, 4,188,388, 4,148,796, 4,128,717, 4,062,858, 4,031,226, 4,020,072, 4,018,895, 4,018,779, 4,013,672, 3,994,898, 3,968,125, 3,939,152, 3,928,356, 3,880,834, 3,668,210; analgesic agents, as disclosed in U.S. Pat. Nos. 5,292,736, 5,688,825, 5,554,789, 5,455,230, 5,292,736, 5,298,522, 5,216,165, 5,438,064, 5,2.04,365, 5,017,578, 4,906,655, 4,906,655, 4,994,450, 4,749,792, 4,980,365, 4,794,110, 4,670,541, 4,737,493, 4,622,326, 4,536,512, 4,719,231, 4,533,671, 4,552,866, 4,539,312, 4,569,942, 4,681,879, 4,511,724, 4,556,672, 4,721,712, 4,474,806, 4,595,6$6, 4,440,779, 4,434,175, 4,608,374, 4,395,402, 4,400,534, 4,374,139, 4,361,583, 4,252,816, 4,251,530, 5,874,459, 5,688,825, 5,554,789, 5,455,230, 5,48,064, 5,298,522, 5,216,165, 5,204,365, 5,030,639, 5,017,578, 5,008,264, 4,994,450, 4,980,365, 4,906,655, 4,847,290, 4,844,907, 4,794,110, 4,791,129, 4,774,256, 4,749,792, 4,737,493, 4,721,712, 4,719,231, 4,681,879, 4,6'70,541, 4,667,03,9, 4,658;037, 4,634,708, 4,623,648, 4,622,326, 4,608,374, 4,595,686, 4,594,188, 4,569,942, 4,556,672, 4,552,866, 4,539,312, 4,536,512, 4,533,671, 4,511,724, 4,4~10,779, 4,434,175, 4,400,534, 4,395,402, 4,391,827, 4,374,139, 4,361,583, 4,322,420, 4,306,097, 4,252,816, 4,251,530, 4,244,955, 4,232,018, 4,209,520, 4,164,514, 4,147,872, 4,133,$19, 4,124,71'3, 4,117,012, 4,064,272, 4,022,836, 3,966,944; cholinergic agents, as disclosed in U.S. Pat, Nos. 5,219,872, 5,219,873, 5,073,560, 5,073,560, 5,346,911, 5,424,301, 5,073,560, 5,219,872, 4,900,748, 4,786,648, 4,798,841, 4,782,071, 4,710,508, 5,482,938, 5,464,842, 5,378,723, 5,346,911, 5,318,978, 5,219,873, 5,219,872, 5,084,281, 5,073,560, S,OCI2,955, 4,988,710, 4,900,748, 4,798,841, 4,786,648, 4,782,071, 4,745,123, 4,710,508; adrenergic agents, as disclosed in U.S. Pat. Nos. 5,091,528, 5,091,528, 4,835,157, 5,708,015, 5,594,027, 5,580,892, 5,576,332, 5,510,376, 5,482,961, 5,334,601, 5,202,347, 5,135,926, 5,116,867, 5,091,528, 5,017,618, 4,835,157, 4,829,086, 4,579,867, 4,568,679, 4,469,690, 4,395,559, 4,381,309, 4,363,808, 4,343,800, 4,329,289, 4,314,943, 4,311,708, 4,304,721, 4,296,117, 4,285,873, 4,281,189, 4,278,608, 4,247,710, 4,145,550, 4,145,425, 4,139,535, 4,082,843, 4,011,321, 4,001,421, PATENT
3,982,010, 3,940,407, 3,852,468, 3,832,470; antihistamine agents, as disclosed in U.S. Pat.
Nos. 5,874,479, 5,863,938, 5,856,364, 5,770,612, 5,702,688, 5,674,912, 5,663,208, 5,658,957, 5,652,274, 5,648,380, 5,646,190, 5,641,814, 5,633,285, 5,614,561, 5,602,183, 4,923,892, 4,782,058, 4,393,210, 4,180,583, 3,965,257, 3,946,022, 3,931,197;
steroidal agents, as disclosed in U.S. Pat. Nos. 5,863,538, 5,855,907, 5,855,866, 5,780,592, 5,776,427, 5,651,987, 5,346,887, 5,256,408, 5,252,319, 5,209,926, 4,996,335, 4,927,807, 4,910,192, 4,710,495, 4,049,805, 4,004,005, 3,670,079, 3,608,076, 5,892,028, 5,888,995, 5,883,087, 5,880,115, 5,869,475, 5,866,558, 5,861,390, 5,861,388, 5,854,235, 5,837,698, 5,834,452, 5,830,886, 5,792,758, 5,792,757, 5,763,361, 5,744,462, 5,741,787, 5,741,786, 5,733,899, 5,731,345, 5,723,638, 5,721,226, 5,712,264, 5,712,263, 5,710,144, 5,707,984, 5,705,494, 5,700,793, 5,698,720, 5,698,545, 5,696,106, 5,677,293, 5,674,861, 5,661,141, 5,656,621, 5,fi46,136, 5,637,691, 5,616,574, 5,614,514, 5,604,215, 5,604,213, 5,599,807, 5,585,482, 5,565,588, 5,563,259, 5,563,131, 5,561,124, 5,556,845, 5,547,949, 5,536,714, 5,527,806, 5,506,354, 5,506,221, 5,494,907, 5,491,136, 5,478,956, 5,426,179, 5,422,262, 5,391,776, 5,382,661, 5,380,841, 5,380,840, 5,380,839, 5,373,095, 5,3X,078, 5,352,809, 5,344,827, 5,344,826, 5,338,837, 5,336,686, 5,292,906, 5,292,878, 5,281,587, 5,272,140, 5,244,886, 5,236,912, 5,232,915, 5,219,879, 5,218,109, 5,215,972, 5,f.12,166, 5,206,415, 5,194,602, 5,166,201, 5,166,055, 5,126,488, 5,116,829, 5,108,996, 5,099,037, 5,096,892, 5,09:3,502, 5,086,047, 5,084,450, 5,082,835, 5,081,114, 5,053,404, 5,041,433, 5,041,432, 5,034,548, 5,032,586, 5,026,882, 4,996,335, 4;975,537, 4,970,205, 4,954,446, 4,950,428, 4,946,834, .
4,937,237, 4,921,$46, 4,920,099, 4,910,226, 4,900,725, 4,892,867, 4,888,336, 4,885,280, 4,882,322, 4,882,319, 4,882,315, 4,874,855, 4,868,167, 4,865,767, 4,861,875, 4,861,765, 4,861,763, 4,847,014, 4,774,236, 4,753,932, 4,711,856, 4,710,495, 4,701,450, 4,701,449, ' 4,689,410, 4,680,290, 4,670,551, 4,664,850, 4,659,516, 4,647,410, 4,634,695, 4,634,693, 4,588,530, 4,567,000, 4,560,557, 4,558,041, 4,552,871, 4,552,868, 4,541,956, 4,519,946, 4,515,787,4,512,986, 4,502,989,4,495,102; the disclosures of all the above of which are herein incorporated by reference.
[0057]Cancer chemotherapeutic agents for use in the invention in principle include drugs which may be useful for treating brain tumors or other neoplasia in or around the brain. Such chemotherapeutic agents include adriamycin (also known as doxorubicin), cisplatin, paclitaxel, analogs thereof, and other chemotherapeutic agents demonstrate activity against tumours ex vivo and in vivo. Such chemotherapeutic agents also include alkylating agents, antimetabolites, natural products (such as vinca alkaloids, epidophyllotoxins, antibiotics, enzymes and biological response modifiers}, topoisomerase inhibitors, microtubule PATENT
inhibitors, spindle poisons, hormones and antagonists, and miscellaneous agents such as platinum coordination complexes, anthracendiones, substituted areas, etc.
Those of skill in the art will know of other chemotherapeutic agents.
[0058] In embodiments, the drug is not for use in treating a nasal condition, e.g, is not a decongestant such as , for example, oxymetazoline or is not an antiviral agent such as, for example, amantadine. In other embodiments the drug is not useful for treating a nasal or respiratory tract infection. Included also are embodiments in which the drug is not useful for treating a nasal or respiratory tract disease or disorder.
[0059] Included in the invention therefore pharmaceutical formulations for delivery by nasal administration of a drug for the treatment of a disorder of the central nervous system to a mammalian nervous system, comprising:
the drug; and an eriodictyon fluid extract.
The invention includes such formulations adapted for nasal administration.
[0060] In embodiments, the drug is selected from the group consisting of analgesics; opiates;
antibiotics;,anticholinergic agents; antidiabetic agents; antinauseants;
antineoplastic agents;
antipsychotics; steroids, therapeutic peptides; compositions far treating drug withdrawal;
psychopharmacological agents; peripheral nervous system drugs; drugs acting at synaptic or neuroeffector functional sites; smooth muscle active drugs; histamines and antihistamines;
anti-infective agents; cytostatics; antimalarials; aniiprotozoim agents.
[0061] In more particular embodiments, the drug is selected from the group consisting of analgesics; opiates; antinauseants; antipsychotics; compositions for treating drug withdrawal;
psychopharmacological agents; peripheral nervous system drugs; drugs acting at synaptic or neuroeffector functional sites; smooth muscle active drugs.
[0062]In other particular embodiments, the drug is selected i:rom the group consisting of antibiotics; antivirals; antimalarials; antiprotozoan agents.
[0063) The pharmaceutical compositions and systems of the invention can be used in different ways to accomplish somewhat different purposes. The drug delivery device described above is preferred for administering drugs to the olfactory nerve via an intranasal PATENT
administration route, and the eriodictyon fluid present in the excipient composition is useful in signifcantiy reducing local irritation or sensitization that so frequently occurs with this type of drug delivery. Furthermore, the eriodictyon fluid facilitates adherence of the drug to the mucosal tissue.
[0064] In an exemplary embodiment, at least 60% of the uptake of an administered dose of the drug is taken-up by the nervous system, rather than the vasculature route (i.e., direct delivery to the nervous system, rather than systemic delivery through the vasculature, leading up to the nervous system uptake). In a preferred embodiment, at Least 70% of the uptake of an administered dose of the drug is taken-up by the nervous system, rather than the vasculature route. In a more preferred embodiment, at least 80% of the uptake of an administered dose of the drug is taken-up by the nervous system, rather than the vasculature route. In an even more preferred embodiment, at least 90°~0 of the uptake of an adnunistered dose of the drug is taken-up by the nervous system, rather than the vasculature route. In the most preferred embodiment, at least 100% of the uptake of an administered dose of the drug is taken-up by the nervous system, rather than the vasculature route.
[0065] The materials, methods and devices of the present invention are further illustrated by the examples, which follow. 'these examples arc offered to illustrate, but not to limit the claimed invention.
EXAMPLES
[0066] A solution of oxymetazoline for nasal administration was prepared as summarized in the following table:
Components Quantity Water 90.0 wt.
Eriodictyon Fluid Extract 2.5 wt.
pH Buffer 1.5 wt.
Sodium Chloride 5.0 wt.
Oxymetazoline 1.0 wt.
[OOG7] The above composition is useful as a nasal spray. The composition may further include other active components as desired. The sodium chloride is added in an amount to PATENT
adjust to the saline composition of nornial nasal mucosal tissues, as is the pH of the composition.
[0068] A solution of amantadine for nasal administration to the olfactory nerve was prepared as summarized in the following table:
Components Quantity Water 90.0 wt.
Eriodictyon Fluid Extract 2.5 wt.
pH Buffer 1.5 wt.
Sodium Chloride 5.0 wt.
Amantadine 1.0 wt.
[0069] The solution is buffered as described in the preceding example.
[0070] A formulation of eriodictyon fluid extract was prepared as summarized in the following table:
Components Quantity 8xcipient (carrier) 1.0-99 wt.
Yerba Santa Fluid Extract* 99-1.0 wt.
Other Components 0-9.0 wt.
~ lJried eriodictyon can be obtained from Meer Corporation, North Bergen, New Jersey. It can be used to prepare the fluid extract in a manner substantially as described in Remington's Pharmaceutical Sciences, 17th Ed., cited supra, on pages 1286 and 1516. After preparation of the extract, the above ingredients can be mixed to give a formulation of Yerba Santa extract.
[0071] It is understood that the examples and embodiments described herein are for illustrative purposes only and that various modifications or changes in light thereof will be PATENT
suggested to persons skilled in the art and are to be included within the spirit and purview of this application and scope of the appended claims. All pulblications, patents, and patent applications cited herein are hereby incorporated by reference in their entirety for all purposes.
See, e.g., A. R. Hutchens, Indian Herbalogy of North America, Ontario: Merco, 19'75, at pp.
3I7-318. A number of references to the Yerba Santa plant teach its use as an expectorant (e.g., N. Coon, The Dictionary of Useful Plants, Emmaus, .Pa.: Rodale Press, 1974)), in treating colds, sore throats, catarrh, stomach aches, vomiting and diarrhea (see A. R.
Hutchens, supra), in treating hemorrhoids (D. G. Spoerke, :Herbal Medications, Santa Barbara, Cali~: Woodbridge Press, 1980, at p. 183), in treating diseases of the lung (Los Remedios de la Gente: A Compilation of Traditional New Mexican Hcrbal Medicines and Their Use, compiled by M. Moore, 1977}, and in masking t:he taste of quinine and other bitter medications (Spoerke, supra; see also G. E. Trease et al., Pharmacognosy, London: Cassell 8c Colber, 1978, at p. 463}). References related to the Yerba Manta plant, in addition to the Coon, Hutchens, Moore, Spoerke, and Trease et al. references cited in the preceding section, include V. J. Vogel, American Indian Medicine, The University of Oklahoma Press, 1970, at pp. 83, 399-400; W. H. Lewis et al., Medical Botany; Plants Affecting Man's Health, New York: John Wiley. & Sons, 1977, at p. 301; P. I-luson, Mastf~ring IIerbalism:
A Practical Guide, New York: Stein and Day, 1974, at p. 32; B. C. Harris, The Compleat Herbal, Barre, Mass.; Bane Publishers; 1972, at p. 197; N. Coon, Using Plants for Healing, Hcarthside Press, 1963, at p. 122; M. Grieve, A Modern Herbal, vol. 2 2, New York: Hafner publishing Co., 1969, at p. 865; and V. E. Tyler et al., Pharmacognosy, Philadelphia: Lee & Febiger, 1981, at p. 148:
[0006 Most of the efforts currently under way to discover new therapeutic drugs for disorders of the central nervous system (CNS) face the problem of delivering the drugs to the brain without impairing the activity or integrity of such substances or compounds, while minimizing systemic adverse effects. And that means finding a way around--or through--the blood brain barrier (BBB), the physiological barrier between bloodstream and brain.
[0007) Accordingly, it is a primary object of the present invention to address the above-identified need in the art, and to provide methods, compositions and drug delivery systems for transmucosal drug administration, specifically to the olfactory nerve, which involve the use of eriodictyon fluid extract as an excipient.
PATENT
[0008] The method provides an advantage by virtue of the intranasal administration of the medication to the olfactory nerve. The olfactory nerve provides a direct connection between the outside environment and the brain thus providing quick: and ready delivery of active agents for treatment of various disorders, however, delivery of drugs to the olfactory nerve must be approached with caution as the nasal mucosa in general and the olfactory neuroepithetium in particular are much more delicate and susceptible to damage than skin.
Furthermore, the olfactory neuroepithelium is a very specialized type of epithelium that has a limited surface area and a poor regeneration potential. Thus, formulations for delivery to the olfactory nerve must be minimally irritating. Furthermore, it is generally desired that the formulations deliver the drug in a highly effective manner, thereby minimizing the number of applications necessary and reducing the opportunities for irritation of the olfactory nerve.
[0009] The methods and compositions of the invention are based on the discovery that eriodictyon fluid extract is extremely effective in ameliorating the problems associated with delivery of drugs to the mucosa. Thus, formulations for dellivery of active agents to the olfactory nerve, which are formulated with eriodictyon fluid extract have unexpectedly beneficial properties, including being less irritating to the mucosa and more effectively delivering the active agent to the desired site due to the ability of the extract to adhere to the surface of the olfactory nerve.
[0010] In one aspect of the invention, a system is provided for delivering a drug to the olfactory nerve, the system comprising:
(a) a source of the drug to be administered;
(b) a source of an excipient composition comprising eriodictyon fluid extract;
and (c) a pressurized delivery device, configured to deliver the drug and excipient to the olfactory nerve.
[0011] In another aspect, the invention encompasses pharmaceutical compositions containing a drug and the eriodictyon-based excipient. These compositions may be simply a mixture of drug and eriodictyon fluid extract, wherein the eriodictyon fluid extract serves as an excipient, or they may be mixtures of drug, eriodictyon-based excipient, and one or more vehicles, carriers, diluents, permeation enhancers, or the like. The composition may be in the form of a solution, suspension, ointment, gel, cream, etc.
(0012] In still another aspect, the invention is directed to a method of facilitating adherence of an agent to the olfactory nerve, the method involving appl'.ying the agent to the olfactory nexve in conjunction with an excipient composition containing eriodictyon fluid extract. This aspect of the invention is based on the discovery that eriodictyon fluid extract is useful as a PATENT
bioadhesive, i.e., a species which will increase adhesion olFa device (e.g., a transdermal drug delivery device) or chemical species (such as a drug in an ointment, gel, solution or suspension) to the skin or mucosal tissue. In related aspects, other methods of using compositions containing eriodictyon fluid extract are provided.
[0013] Additional objects, aspects and advantages of the present invention axe set forth in the detailed description that follows.
[0014] FIG. 1, comprising F1GS.1A to 1B, sets forth an exemplary bag on valve delivery system of use in the present invention.
DETAILED DESCRIPTION OF THIS INVENTION
[0015] Before describing the present compositions, systems and methods of the invention in detail, it is to be understood that this invention is not linvted to the particular drugs, delivery systems, or dosage regimens described herein as such may, of course, vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to be limiting since the scope of the present invention will be limited only by the appended claims.
10016] It must be noted that, as used in this specification and the appended claims, the singular forms "a," "an" and "the" include plural referents unless the context clearly dictates otherwise. Thus, for example, reference to a. laminated structure containing "a drug" includes a mixture of two or more drugs, reference to "an adhesive" includes reference to one or more of such adhesives, and reference to "a solvent" includes reference to a mixture of two or more solvents. ' [0017] Other definitions of words and phrases used throughout this specification and the appended claims are as follows.
[0018] The term "drug" as used herein is intended to mean a compound or composition of matter which, when administered to an organism (human or animal) induces a desired pharmacologie and/or physiologic effect by local andlor systemic action. In general, the terms include the therapeutic or prophylactic agents in all major tlaerapeutic/prophylactic areas of medicine. Examples of drugs useful in conjunction with the: present invention include: anti-infectives such as antibiotics and antiviral agents; analgesics and analgesic combinations;
anorexics; anticholinergic agents; anticonvulsants; antidepressants;
antidiabetic agents;
antihistamines; anti-inflammatory agents, antimigraine preparations; anti-motion sickness PATENT
drugs; antinauseants; antineoplastics; antiparkinsonism drugs; antipruritics;
antipsychotics;
antipyretics; antispasmodics; sympathomimetics; xanthine derivatives;
cardiovascular preparations including calcium channel blockers and beta-blockers such as pindolol and antiarrhythmics; antihypertensives; diuretics; vasodilators including general coronary, peripheral and cerebral; central nervous system stimulants; cough and cold preparations, including decongestants; steroids; hypnotics; immunosuppressives; muscle relaxants;
parasympatholytics; psychostimulants; sedatives; tranquilizers; and agents for alleviating drug withdrawal symptoms.
[0019] The term "effective amount" as used herein intends that quantity of material which, when used or administered to a patient as indicated, is sufficient to provide the desired or intended beneficial effect. An "effective amount" of eriodictyon fluid extract to alleviate chemically induced irritation, e.g., irritation resulting from~topical, transdermal or transmucosal administration of a drug, is an amount which is sufficient to provide a desired degree of relief. Again, the "effective amount" in this latter case will vary with the individual, the degree of irritation, and possibly with the particular type of chemical or drug, if any, which is inducing the irritation.
[0020] By "eriodictyon fluid extract" or "Yerba Santa fluid extract" as used herein is meant the fluid which may be extracted from dried Yerba Santa leaves. One exemplary method for obtaining this Yerba Santa fluid extract is set forth in Remi:ngton's Pharmaceutical Sciences, 17th Ed., 1985, at pp. 128b and 1516, which is incorporated herein by reference to disclose such an extraction method. As described in detail in the aforementioned reference, the dried Yerba Santa plant is preferably processed in alcohol and water, followed by straining, pressing and clarification by, for example, decantation or filtration.
[0021] "Carriers" or "vehicles" as used herein refer to carrier materials suitable for transdermal, transmucosal or topical drug administration, and include any such materials known in the art, e.g., any liquid, gel, solvent, liquid diluenl;, solubilizer, or the like, which is nontoxic and which does not interact with other component's of the particular composition or system in a deleterious manner. Examples of suitable carriers for use herein include water, mineral oil, silicone, nontoxic organic solvents, petroleum jelly, and a variety of other materials. The particular carrier or vehicle selected will depend on the particular system used, the desired rate of drug administration, as well as on the particular drug and its solubility in various solvents.
[0022] "Permeation-enhancement agent" refers to excipients in a composition for intranasal drug administration that enhance overall delivery, dose consistency andlor pharmaceutical PATENT
acceptance. The methods for assessing enhancement are duantitative and are defined in the examples herein. Functional in vitro cell-based testing and methods are used to compare the effects of drug molecule by itself versus the same mass of drug molecule formulated and administered with excipients. "Enhancement" is a rnultiva.riant value proposition encompassing total bioavailability, net uptake, consistency of uptake and dosing, drug metabolism, degradation during dosing, drug targeting to active site(s), mucosal irritation, and overall safety and toxicity. In some cases, the relative benefit of the drug is used to optimize the excipient composition of the formulation, even at the expense of factors such as comfort and side effects. As explained when "pharmaceutical acceptance" was defined, the benefits of therapy may outweigh the discomfort of delivery. Chronic administration must also be considered. However, comfort and safety are optinnized when overall delivery is not unacceptably compromised. As an illustration of the balance, pH may improve the stability of a drug and its transmucosal flux, but a formulation pH outside the range of pH 3 to 8.5 may result in pain and tissue damage when administered nasally.
Introduction [0023] It has long been known that the bulk of the brain and the spinal cord is surrounded by a specially secreted clear fluid called the cerebrospinal fluid (CSF).
Chemical substances such as metabolites move relatively freely from the alimentary canal into the blood, but not into the CSF. As a result, the blood levels of sugars, amino acids or fatty acids fluctuate ovex wide range while their concentrations in the CSF remain relatively stable. The same is true for hormones, antibodies, certain electrolytes, and a variety of drugs.
Injected directly into the blood, they act rapidly on peripheral tissues such as the muscles, heart, or glands but they have little or no effect on the central nervous system (CNS).
[0024] When administered into the CSF, however, the same substances exert a prompt and strong action. The conclusion is that the substances injected into the blood do not reach the CSF and the brain with sufficient rapidity and in an effective concentration.
[0025] 'the way in which the brain keeps its environment constant is frequently discussed in terms of a blood-brain barrier (BBB). Once substances have found their way into the CSF, they are free to diffuse into the tissues of the brain. The entry of hydrophilic and relatively large molecules into the CNS is restricted by the existence of a BBB. The BBB
separates the brain from the blood circulation and is involved in the homeostasis of the brain. The BBB is situated in the brain microvessels and is composed of various cell types like endothelial cells, PATENT
astrocytes, microglial cells, perivascular macrophages, and pericytes. The cerebral and endothelial cells form the morphological and functional basis of the BBB.
j0026] The olfactory area is located high in the nasal vault above the superior turbinate.
Sensory hairs extend from the surface of the olfactory area to the cells that lie deep in the mucosa. Nerve fibers subserving the sense of smell have tlneir cells of origin in the mucous membrane of the upper and posterior parts of the nasal cavity. The entire olfactory mucosa covers an area of about 2.5 cm2. The central processes of olfactory fila are very fine urunyelinated fibers that converge to form small fascicles enwrapped by Schwann cells and pass through openings in the cribriform plate of the ethmoid bone into the olfactory bulb.
The axons of the mitral and tufted enter the olfactory tract, which courses along the olfactory groove of the cribriform plate to the cerebrum. Some fibers project to the medial dorsal nucleus of the thalamus and the hypothalamus. That olfactory stimuli and emotional stimuli are strongly linked is not surprising, in view of their common roots in the limbic system.
(0027] According to Belt, the olfactory system has direct rneuroanatomical and neurophysiological input to the amygdala and eventually hippocampus. Therefore it is conceivable that chemical stimuli at low levels could trigger limbic dysfunction in patients who happen to meet descriptive criteria for somatization disorder. It is also stated that there is no blood-brain barrier in the nasal passages. The limbic structure (e.g.
the amygdala, olfactory bulb and hippocampus) can become easily kindled. The olfactory nerves can transport toxins directly to the limbic system. This may result in symptoms including .
memory loss, irritable bowel, and migraine headaches.
[0028) It has been suggested by Shipley, that it is possible to transport substances which come into contact with the nasal epithelium to the brain and that it is thus possible to ' influence the function of neurons in the brain, including some which have extensive projection to wide areas of the CNS.
[0029] The optic nerve, mediating vision, is distributed to the eyeball. Most of its fibers are afferent and originate in the nerve cells of the ganglionic layer of the retina.
Developmentally, the optic nerves and the retinae are parts of the brain and their fibers with glia.
(0030] The optic nerve, about 4 cm long, is directed backwards and medially through the posterior part of the orbital cavity. It then runs through the optic canal into cranial cavity and joins the optic chiasma. The optic nerve is enclosed in three sheaths, which are continuous with the membranes of the brain, and are prolonged as far as the back of the eyeball.
Therefore, lhcrc is a direct connection between the optic nerve and the brain structures.
PATENT
[0031] Itaya and van Hoesen described transneuronal retrograde labeling of neurons in the stratum griseum superficiale ofthe superior colliculus following intraoeular injection of wheat germ agglutinin-horseradish peroxidase. A study of the distribution of wheat germ agglutinin-horseradish peroxidase in the visual system following intraocular injections in the chick, rat and monkey confirmed early findings of transneiual transport of this conjugate in vivo.
[0032) From the overview of the literature given above we can conclude the following.
Many substances such as metabolic products, drugs, and other substances cannot or only to a limited extent cross the BBB from the blood into the brain. From the nasal cavity these substances can penetrate into the brain because in the area of 2.5 cm2 of the upper posterior part of the nasal cavity, the BBB does not exist. Therefore., substances introduced into the upper part of the nasal cavity can directly enter the brain. Access to the CNS
is also possible through the optic nerve.
THE EMBODIMENTS.
[0033] In one aspect of the invention, a system is provided for delivering a drug to the olfactory nerve, the system comprising:
(a} a source of the drug to be administered;
(b) a source of an excipient composition comprising eriodictyon fluid extract;
and (e) a pressurized delivery device, configured to deliver the drug and excipient to the olfactory nerve.
[0034] In an exemplary embodiment, the pressurized device is a bag on valve device such as that illustrated in FIG. lA. The device includes an optionally detachable delivery nozzle or head, which is configured to deliver the drug and excipient to the olfactory nerve (FIG. 1B}.
In operation, the nozzle is inserted into the nasal cavity to the proper depth and a charge of the dxug/excipient composition is administered within the nasal cavity, traveling to at least the upper third of the nasal cavity where an amount of the drug effective to achieve a desired result is absorbed through the olfactory nerve into the CNS.
[0035] An exemplary nozzle of use in the system of the invention, and in practicing the invention has a length insertable into the nasal cavity of from about 1 cm to about 3 cm.
[0036] The method of the invention delivers the agent to the nasal cavity of a mammal. It is preferred that the agent be delivered to the olfactory area in the upper third of the nasal cavity and particularly to the olfactory epithelium in order to promote transport of the agent into the peripheral olfactory neurons rather than the capillaries within the respiratory epithelium. The PATENT
invention prefers the transport of agents to the brain by means of the nervous system instead of the circulatory system so that potentially therapeutic agents that are unable to cross the blood-brain barrier from the bloodstream into the brain may be delivered to the brain.
[0037] In a particularly preferred embodiment, the amount of drug absorbed through the olfactory nerve from a formulation of the instant invention is greater than the amount absorbed through this nerve from a formulation that does not include the erlodictyon extract.
More preferably, the amount of drug absorbed by the olfactory nerve from a formulation of the instant invention per unit time is greater than that absorbed from a formulation that does not include the eriodictyon extract. Still other preferred embodiments result in a lower frequency or a lesser degree of irritation of the nasal cavity and/or olfactory nerve upon administration of a formulation of the invention when compared to an analogous formulation that does not include the eriodictyon extract.
[0038] It is preferred that the agent is capable of at least partially dissolving in the fluids that are secreted by the mucous membrane that surround the cilia of the olfactory receptor cells of the olfactory epithelium in order to be absorbed into the olfactory neurons.
Alternatively, the invention may combine the agent with a carrier and/or other substances that faster dissolution of the agent within nasal secretions. Useful adjuvants include lipids, e.g., GM-1, phosphatidylserine (PS), and emulsifiers such as polysorbate 80.
[0039] To further facilitate the transport of the agent into the olfactory system, the method of the present invention combines the agent with a substance, e.g., er~iodictyon extract, that enhances the residence time of the agent in contact with the olfactory epithelium, thereby enhancing absorption of the agent through the olfactory epithelium. It is generally preferred that the additives promote the retention of the agent in contrct with the peripheral olfactory receptor cells. These peripheral neurons provide a direct connection between the brain and the outside environment due to their role in odor detection.
(0040] If the inherent permeability of mucosal tissue to some drugs (e.g., steroids) is too low to permit therapeutic levels of drugs to pass through a reasonably sized area of unbroken mucosa, a permeation enhancer can be administered with such drugs.
Accordingly, in such cases, the enhancer will be present in the drug/excipient formulation.
[0041] Thus, in another exemplary embodiment, the agent includes a permeation-enhancing agent that increases permeation of the drug into the olfactory nerve.
Permeation-enhancing agents are selected from the groups consisting of bile acids, bile salts, ionic, nonionic zwitterionic, anionic, cationic, gemini pair surfactants, phos~pholipids, alcohols, glycyrrhetinic acid and its derivatives, enamines, salicylic acid and sodium salicylate, acetoaeetate glycerol PATENT
esters, dimethylsulfoxide, n-methylpyrrolinidinone, cycloalextrins, medium chain fatty acids, short chain fatty acids, short and medium chain diglycerides, short and medium chain monoglycerides, short chain triglycerides, calcium chelato:rs, amino acids, cationic amino acids, homopolymerie peptides, cationic peptides, n-acetylamino acids and their salts, degradative enzymes, fatty acid synthesis inhibitors, cholesterol synthesis inhibitors.
[0042] Permeation enhancers are screened on a case-by-case basis to determine the most suitable candidate. Various models have been studied, for example those of LeCluyse and Sutton (1997. "In vitro models for selection of development candidates.
Permeability studies to define mechanisms of permeation enhancement" Advanced Drug Delivery Reviews, 23:163-I 83). In vztro methods with the EpiAirway model lhave proven to be valuable.
[0043] It is preferred chat the permeation-enhancing agent is lipophilic in order to promote absorption into the olfactory neurons and through the olfactory epithelium.
Among; those permeation-enhancing agents that are lipophilic are lipids, n.g., gangliosides and phosphatidylserine (PS). Uptake ofnon-lipophilic agents, e.g., nerve growth factor (NGF), may be enhanced by the combination with a lipophilic subsaance.
[0044] In one embodiment of the method of the invention, the drug may be combined with micelles comprised of lipophilic substances. Such micelles may modify the permeability of the nasal membrane and enhance absorption of the agent. Among the Iipophilic micelles that are preferred are gangliosides, particularly GM-1 ganglioside, and phosphatidylserine (PS).
The neurologie agent may be combined with one or several types of micelle substances.
[0045] Once the drug has crossed the olfactory epithelium, the invention further provides for transport of the neurologic agent along the olfactory neural pathway and generally into the CNS. The agent itself may be capable of movement within the olfactory system.
In particular, neurotrophic and neuritogenic substances have demonstrated ready incorporation into nerve cell membranes and an affinity for nerve cell receptor sites.
Indications are that these substances are naturally synthesized in tissues in response to neural stimulation and that they subsequently bind to receptors on neurons where they act as nerve growth promoting factors.
[0046] An exemplary drug delivery system of the invention contain a source of drug, a source of a pharmaceutically acceptable excipient composition containing eriodictyon fluid extract. Generally, the system is configured to deliver both the selected drug and the:
eriodictyon fluid to the desired area. The system also provides a means for propelling the agent and extract through the nasal cavity a sufficient distance to bring the agent and extract into operative contact with the olfactory nerve.
PATENT
[0047] The drug/excipient composition contained within the device and delivered therefrom to the olfactory nerve may take a number of forms. The drug and extract may be delivered "neat;' i.e., in the absence of additional liquid. Alternatively, the drug and extract may be dissolved, dispersed or suspended in a suitable pharmaceutically acceptable solvent. The excipient composition contains eriodictyon fluid extract as its active ingredient, and may or may not contain any additional components. Typically, the excipient composition will be eriodictyon fluid extxact itself. In some cases, however, other carriers or vehicles as described above may be incorporated into the excipient composition as well. Still other components can be incorporated into the excipient composition, including preservatives, stabilisers, surfactants, coloring agents, and the like. The drug/excipient composition in the reservoir will typically contain on the order of 0.1 to 20.0 wt. %, more preferably about 0.1 to 10.0 wt.
%, most preferably about 0.5 to 5.0 wt. %, eriodictyon fluid extract (i.e., relative to the total drug/excipient composition), with the amount of drug dependent on a variety of factors, including the desired rate of delivery, the desired dosage, the disease to be treated, the nature and activity of the drug, the desired effect, possible adverse reactions, the ability and speed of the agent selected to reach its intended target, and other factors within the particular knowledge of the patient and the physician.
[0048] The eriodictyon fluid extract itself is an excellent source of antioxidants and can serve as a preservative for oxidation-sensitive drug substances (Liu, J, Nat. Prod.
55: 357-363 (1992); Arriaga-Giner, Z. Naturforsch. 43: 5-6 (1988)). Moreover, the role of reactive oxygen species (ROS) in various disease states is well-recognized. Thus, even in.the absence of a drug, delivery of the anti-oxidants of the eriodictyon fluid extract to the CNS through the olfactory nerve provides a modality for treating and preventing a condition in which .
oxidation, e.g., by ROS, is implicated. Thus, the present invention also provides methods and systems for the delivery of anti-oxidants to the CNS by delivery of a composition containing these anti-oxidants to the olfactory nerve. Exemplary anti-oxidants are those typically found in eriodictyon fluid extract, e.g., flavoncs.
[0049] In still another preferred embodiment, the composition has anti-cancer chemotherapeutic properties. The properties can be derived from species present in the eriodictyon fluid extract, or they can be added to the extract.
[0050] As noted above, a wide variety of drugs (active agents) can be used in conjunction with the compositions and devices of the present invention. Preferred drugs within the classes identified earlier herein include but are not limited to~ the following: analgesics such as aspirin, ibuprofen and acetaminophen; opiates such as morphine; antibiotics such as PATENT
sulfacetamide, clindamycin and erythromycin; anticholinergic agents such as scopolamine;
antidiabetic agents such as insulin; antifungal agents such as nystatin and amphotericin B;
antiviral agents such as amantadine and acyclovir; antihistamines such as diphenhydramine;
antinauseants such as meclozine; antineoplastic agents such as fluorouracil and methotrexate;
antipsychotics such as prochlorperazine; steroids such as hydrocortisone, progesterone, and estrogens, therapeutic peptides such as growth factors, antibodies, insulin;
and compositions for treating drug withdrawal containing, e.g., a CNS stimullant such as caffeine and a serotonin antagonist such as dihydroergotamine or a salt thereof (such compositions are described in applicant's co-pending, commonly assigned U.S. patent application Ser. No.
07/500,034, filed 27 Mar. 1990, now U.S. Pat. No. 5,051,426, and entitled "Method and Compositions for Effecting Withdrawal from Drug Dependency", the disclosure of which is incorporated by reference herein).
[0051] Suitable active agents include, but are not limited tc>, psychopharmacological agents, such as (1) central nervous system depressants, e.g., general anesthetics (barbiturates, benzodiazepines, steroids, cyclohexanone derivatives, and miscellaneous agents), sedative-hypnotics (benzodiazepines, barbiturates, piperidinediones and triones, quinazoline derivatives, carbamates, aldehydes and derivatives, amides, acyclic ureides, benzazepines and related drugs, phenothiazines, etc.), central voluntary muscle tone modifying drugs (anticonvulsants, such as hydantoins, barbiturates, oxazolidinediones, succinimides, acylureides, glutarimides, benzodiazepines, secondary and tertiary alcohols, dibenzazepine derivatives, valproic acid and derivatives, GABA analogs, etc.), analgesics (morphine and derivatives, oripavine derivatives, morphinan derivatives, phenylpiperidines, 2,6-methane-3-benzazocaine derivatives, diphenylpropylamines and isosteres, salicylates, p-aminophenol derivatives, 5-pyrazolone derivatives, arylacetic acid derivatives, fenamates and isosteres, ete.) and antiemetics (antictiolinergics, antihistamines, antidlopaminergics, ete.), (2) central nervous system stimulants, e.g., analeptics (respiratory stimulants, eonvulsant stimulants, psychomotor stimulants), narcotic antagonists (morphine derivatives, oripavine derivatives, 2,6-methane-3-benzoxacine derivatives, morphinan derivatives) nootropics, {3) psychopharmacologicals, e.g., anxiolytie sedatives (benzodiazepines, propanediol carbamates) antipsychotics (phenothiazine derivatives, thio~;anthine derivatives, othE~r tricyclic compounds, butyrophenone derivatives and isoster~;s, diphenylbutylamine derivatives, substituted benzamides, arylpiperazine derivatives, indole derivatives, etc.), antidepressants (tricyclic compounds, MAO inhibitors, etc.)" pharmacodynamic agents, such as (1) peripheral nervous system drugs, e.g., local anesthetics (ester derivatives, amide PATENT
derivatives), (2) drugs acting at synaptic or neuroeffector functional sites, e.g., cholinergic agents, cholinergic blocking agents, neuromuscular blocking agents, adrenergic agents, antiadrenergic agents, {3) smooth muscle active drugs, e.g., spasmolytics (anticholinergics, musculotropic spasmolytics), vasodilators, smooth muscle stimulants, (4) histamines and antihistamines, e.g., histamine and derivative thereof (betazole), antihistamines (H,-antagonists, H2-antagonists), histamine metabolism drugs, chemotherapeutic agents, such as (1) anti-infective agents, e.g., ectoparasiticides (chlorinated hydrocarbons, pyrethins, sulfurated compounds), anthelminties, antiprotozoal agents, antimalarial agents, antiamebic agents, antileiscmanial drugs, antitrichomonal agents, antitrypanosomal agents, sulfonamides, antimycobacterial drugs, antiviral ehemotherapeutics, etc., and (2) cytostatics, i.e., antineoplastic agents or cytotoxic drugs, such as alkylating agents, e.g., Mechlorethamine hydrochloride (Nitrogen Mustard, Mustargen, ~-IN2), Cyclophospharnide {Cytovan, Endoxana), Ifosfamide (1FEX), Chlorambucil (Leukeran), Melphalan (Phenylalanine Mustard, L-sarcolysin, Alkeran, L-PAM), Busulfan {Myleran), Thiotepa (Triethylenethiophosphoramide), Carmustine (BiCNU,13CNU), Lomustine (CeeNU, CCNU), Streptozocin (Zanosar) and the like; plant alkaloids, e.g., Vincristine (Oncovin), Vinblastine (Velban, Velbe), Paclitaxel (Taxol), and the like; antimetab~olites, e.g., Methotrexate (MTX), Mercaptopurine (Purinethol, 6-MP), Thioguanine.(6-TG), Fluorouracil {5-FL1), Cytarabine (Cytosar-U, Ara-C), Azacitidine (Mylosar, 5-AZA) and the like; antibiotics, e.g., Dactinomycin (Aetinomyein D, Cosmegen), Doxorubic-in (Adriamyein), Daunorubiein (duanomycin, Cerubidine), Idarubicin (Idamycin), Bleomycin (Blenoxane), Picamycin (Mithramycin, Mithracin), Mitomycin {Mutamycin) and the like, and other anticellular proliferative agents, e.g., Hydroxyurea (Hydrea), Procarbazine (Mutalane), Dacarbazine (DTTC-Dome), Cisplatin (Platinol) Carboplatiri (Paraplatin), Asparaginase (Elspar) Etoposide (VePesid, VP-16-213}, Amsarcrine (AMSA, m-AMSA), M:itotane (Lysodren), Mitoxantrone (Novatrone), and the like. Chemotherapeutic agents may be those which are for treatment of a disease or disorder in the brain or central nervous system of the patient but demonstrate unacceptable systemic toxicity at desired doses. The general systemic toxicity associated with therapeutic levels of such agents may be reduced by their adlministration via the olfactory and/or optical nerves. Contemplated as examples are cardiotoxic compounds that are useful therapeutics but are dose limited by cardiotoxicity [0052] Suitable active agents include, but are not limited to: Antibiotics, such as:
aminoglycosides, e.g., amikacin, apramycin, arbekacin, bambermycins, butirosin, dibekacin, PATENT
dihydrostreptomycin, fortimicin, gentamicin, isepamicin, lcanamycin, micronomcin, neomycin, netilmicin, paromycin, ribostamycin, sisomicin, spectinomycin, streptomycin, tobramycin, trospectomycin; amphenicols, e.g., azidamfen.icol, chloramphenicol, florfenicol, and theimaphenicol; ansamycins, e.g., rifamide, rifampin, rifamycin, rifapentine, rifaximin;
beta.-lactams, e.g., carbacephems, carbapenems, cephalosporins, cehpamycins, monobactams, oxaphems, penieillins; lineosamides, e.g., clinamycin, lineomycin; macrolides, e.g., clarithromycin, dirthromyein, erythromycin, ete.; polypeptides, e.g., amphomycin, bacitracin, capreomycin, etc.; tetracyclines, e.g., apieycline, chlortetracycline, clomocycline, etc.; synthetic antibacterial agents, such as 2,4-diaminopyrimidines, nitrofurans, guinolones and analogs thereof, sulfonamides, sulfones;
[0053] Suitable active agents include, but are not limited to: Antimalarials, such as:
acedapsone, amodiaquin, arteether, artemether, artemisinin, artesunate, atovaquone, bebeerine, berberine, chirata, chlorguanide, chloroquine, chlorprogaunil, cinchona, cinchonidine, cinchonine, cycloguanil, gentiopicrin, halofantrine, hydroxychloroquine, mefloquine hydrochloride, 3-methylarsacetin, pamaquine, plasmocid, primaquine, pyrimethamine, quinacrine, quinidine, quinine, quinocide, quinoline, dibasic sodium arsenate;
[0054]Suitable active agents include, but are not limited to: Antiprotozoan agents, such as:
acranil, tinidazole, ipronidazole, ethylstibamine, pentamidine, acetarsone, aminitrozole, anisomycin, rufuratel, tinidazole, benzidazole, suramin, andl the like.
[0055] Suitable drugs for use as active agents are also listed in: Goodman &
Gilman's, The Pharmacological Basis of Therapeutics (9th Ed) (Goodman et al. eds) (McGraw-Hill) ( t 996);
and 2006 Physician's Desk Reference.
[0056] Suitable active agents include, but are not limited to: antineoplastic agents, as disclosed in U.S. Pat. Nos. 5,880,161, 5,877,206, 5,786,344., 5,760,041, 5,753,668, 5,698,529, 5,684,004, 5,665,7I5, 5,654,484, 5,624,924, 5,61.8,813, 5,610,292, 5,597,831, 5,530,026, 5,525,633, 5,525,606, 5,512,678, 5,508,277, S,4fi3,181, 5,409,893, 5,358,952, 5,318,965, 5,223,503, 5,214,068, 5,196,424, 5,109,024, 5,106,996, 5,101,072, 5,077,404, 5,071,848, 5,066,493, 5,019,390, 4,996,229, 4,996,206, 4,970,318, 4,968,800, 4,962,114, 4,927,828, 4,892,887, 4,889,859, 4,886,790, 4,882,334, 4,882,333, 4,871,746, 4,863,955, 4,849,563, 4,845,216, 4,833,145, 4,$24,955, 4,785,085, 4,684,747, 4,618,685, 4,611,066, PATENT
4,550,187, 4,550,186, 4,544,501, 4,541,956, 4,532,327, 4,490,540, 4,399,283, 4,391,982, 4,3$3,994, 4,294,763, 4,283,394, 4,246,411, 4,214,089, 4,150,231, 4,147,798, 4,056,673, 4,029,661, 4,012,448; psychopharmacological/psychot- ropic agents, as disclosed in U.S. Pat.
Nos. 5,192,799, 5,036,070, 4,778,800, 4,753,951, 4,590,180, 4,690,930, 4,645,773;, 4,427,694, 4,424,202, 4,440,781, 5,686,482, 5,478,828, 5,461,062, 5,387,593, 5,387,586, 5,256,664, 5,192,799, 5,120,733, 5,036,070, 4,977,167, 4,904,663, 4,788,188, 4,778,800, 4,753,951, 4,690,930, 4,645,773, 4,631,285, 4,617,314, 4,E>13,600, 4,590,180, 4,560,684, 4,548,938, 4,529,727, 4,459,306, 4,443,451, 4,440,781, 4,427,694, 4,424,202, 4,397,853, 4,358,451, 4,324,787, 4,314,081, 4,313,896, 4,294,828, 4,277,476, 4,267,328, 4,264,499, 4,231,930, 4,194,009, 4,188,388, 4,148,796, 4,128,717, 4,062,858, 4,031,226, 4,020,072, 4,018,895, 4,018,779, 4,013,672, 3,994,898, 3,968,125, 3,939,152, 3,928,356, 3,880,834, 3,668,210; analgesic agents, as disclosed in U.S. Pat. Nos. 5,292,736, 5,688,825, 5,554,789, 5,455,230, 5,292,736, 5,298,522, 5,216,165, 5,438,064, 5,2.04,365, 5,017,578, 4,906,655, 4,906,655, 4,994,450, 4,749,792, 4,980,365, 4,794,110, 4,670,541, 4,737,493, 4,622,326, 4,536,512, 4,719,231, 4,533,671, 4,552,866, 4,539,312, 4,569,942, 4,681,879, 4,511,724, 4,556,672, 4,721,712, 4,474,806, 4,595,6$6, 4,440,779, 4,434,175, 4,608,374, 4,395,402, 4,400,534, 4,374,139, 4,361,583, 4,252,816, 4,251,530, 5,874,459, 5,688,825, 5,554,789, 5,455,230, 5,48,064, 5,298,522, 5,216,165, 5,204,365, 5,030,639, 5,017,578, 5,008,264, 4,994,450, 4,980,365, 4,906,655, 4,847,290, 4,844,907, 4,794,110, 4,791,129, 4,774,256, 4,749,792, 4,737,493, 4,721,712, 4,719,231, 4,681,879, 4,6'70,541, 4,667,03,9, 4,658;037, 4,634,708, 4,623,648, 4,622,326, 4,608,374, 4,595,686, 4,594,188, 4,569,942, 4,556,672, 4,552,866, 4,539,312, 4,536,512, 4,533,671, 4,511,724, 4,4~10,779, 4,434,175, 4,400,534, 4,395,402, 4,391,827, 4,374,139, 4,361,583, 4,322,420, 4,306,097, 4,252,816, 4,251,530, 4,244,955, 4,232,018, 4,209,520, 4,164,514, 4,147,872, 4,133,$19, 4,124,71'3, 4,117,012, 4,064,272, 4,022,836, 3,966,944; cholinergic agents, as disclosed in U.S. Pat, Nos. 5,219,872, 5,219,873, 5,073,560, 5,073,560, 5,346,911, 5,424,301, 5,073,560, 5,219,872, 4,900,748, 4,786,648, 4,798,841, 4,782,071, 4,710,508, 5,482,938, 5,464,842, 5,378,723, 5,346,911, 5,318,978, 5,219,873, 5,219,872, 5,084,281, 5,073,560, S,OCI2,955, 4,988,710, 4,900,748, 4,798,841, 4,786,648, 4,782,071, 4,745,123, 4,710,508; adrenergic agents, as disclosed in U.S. Pat. Nos. 5,091,528, 5,091,528, 4,835,157, 5,708,015, 5,594,027, 5,580,892, 5,576,332, 5,510,376, 5,482,961, 5,334,601, 5,202,347, 5,135,926, 5,116,867, 5,091,528, 5,017,618, 4,835,157, 4,829,086, 4,579,867, 4,568,679, 4,469,690, 4,395,559, 4,381,309, 4,363,808, 4,343,800, 4,329,289, 4,314,943, 4,311,708, 4,304,721, 4,296,117, 4,285,873, 4,281,189, 4,278,608, 4,247,710, 4,145,550, 4,145,425, 4,139,535, 4,082,843, 4,011,321, 4,001,421, PATENT
3,982,010, 3,940,407, 3,852,468, 3,832,470; antihistamine agents, as disclosed in U.S. Pat.
Nos. 5,874,479, 5,863,938, 5,856,364, 5,770,612, 5,702,688, 5,674,912, 5,663,208, 5,658,957, 5,652,274, 5,648,380, 5,646,190, 5,641,814, 5,633,285, 5,614,561, 5,602,183, 4,923,892, 4,782,058, 4,393,210, 4,180,583, 3,965,257, 3,946,022, 3,931,197;
steroidal agents, as disclosed in U.S. Pat. Nos. 5,863,538, 5,855,907, 5,855,866, 5,780,592, 5,776,427, 5,651,987, 5,346,887, 5,256,408, 5,252,319, 5,209,926, 4,996,335, 4,927,807, 4,910,192, 4,710,495, 4,049,805, 4,004,005, 3,670,079, 3,608,076, 5,892,028, 5,888,995, 5,883,087, 5,880,115, 5,869,475, 5,866,558, 5,861,390, 5,861,388, 5,854,235, 5,837,698, 5,834,452, 5,830,886, 5,792,758, 5,792,757, 5,763,361, 5,744,462, 5,741,787, 5,741,786, 5,733,899, 5,731,345, 5,723,638, 5,721,226, 5,712,264, 5,712,263, 5,710,144, 5,707,984, 5,705,494, 5,700,793, 5,698,720, 5,698,545, 5,696,106, 5,677,293, 5,674,861, 5,661,141, 5,656,621, 5,fi46,136, 5,637,691, 5,616,574, 5,614,514, 5,604,215, 5,604,213, 5,599,807, 5,585,482, 5,565,588, 5,563,259, 5,563,131, 5,561,124, 5,556,845, 5,547,949, 5,536,714, 5,527,806, 5,506,354, 5,506,221, 5,494,907, 5,491,136, 5,478,956, 5,426,179, 5,422,262, 5,391,776, 5,382,661, 5,380,841, 5,380,840, 5,380,839, 5,373,095, 5,3X,078, 5,352,809, 5,344,827, 5,344,826, 5,338,837, 5,336,686, 5,292,906, 5,292,878, 5,281,587, 5,272,140, 5,244,886, 5,236,912, 5,232,915, 5,219,879, 5,218,109, 5,215,972, 5,f.12,166, 5,206,415, 5,194,602, 5,166,201, 5,166,055, 5,126,488, 5,116,829, 5,108,996, 5,099,037, 5,096,892, 5,09:3,502, 5,086,047, 5,084,450, 5,082,835, 5,081,114, 5,053,404, 5,041,433, 5,041,432, 5,034,548, 5,032,586, 5,026,882, 4,996,335, 4;975,537, 4,970,205, 4,954,446, 4,950,428, 4,946,834, .
4,937,237, 4,921,$46, 4,920,099, 4,910,226, 4,900,725, 4,892,867, 4,888,336, 4,885,280, 4,882,322, 4,882,319, 4,882,315, 4,874,855, 4,868,167, 4,865,767, 4,861,875, 4,861,765, 4,861,763, 4,847,014, 4,774,236, 4,753,932, 4,711,856, 4,710,495, 4,701,450, 4,701,449, ' 4,689,410, 4,680,290, 4,670,551, 4,664,850, 4,659,516, 4,647,410, 4,634,695, 4,634,693, 4,588,530, 4,567,000, 4,560,557, 4,558,041, 4,552,871, 4,552,868, 4,541,956, 4,519,946, 4,515,787,4,512,986, 4,502,989,4,495,102; the disclosures of all the above of which are herein incorporated by reference.
[0057]Cancer chemotherapeutic agents for use in the invention in principle include drugs which may be useful for treating brain tumors or other neoplasia in or around the brain. Such chemotherapeutic agents include adriamycin (also known as doxorubicin), cisplatin, paclitaxel, analogs thereof, and other chemotherapeutic agents demonstrate activity against tumours ex vivo and in vivo. Such chemotherapeutic agents also include alkylating agents, antimetabolites, natural products (such as vinca alkaloids, epidophyllotoxins, antibiotics, enzymes and biological response modifiers}, topoisomerase inhibitors, microtubule PATENT
inhibitors, spindle poisons, hormones and antagonists, and miscellaneous agents such as platinum coordination complexes, anthracendiones, substituted areas, etc.
Those of skill in the art will know of other chemotherapeutic agents.
[0058] In embodiments, the drug is not for use in treating a nasal condition, e.g, is not a decongestant such as , for example, oxymetazoline or is not an antiviral agent such as, for example, amantadine. In other embodiments the drug is not useful for treating a nasal or respiratory tract infection. Included also are embodiments in which the drug is not useful for treating a nasal or respiratory tract disease or disorder.
[0059] Included in the invention therefore pharmaceutical formulations for delivery by nasal administration of a drug for the treatment of a disorder of the central nervous system to a mammalian nervous system, comprising:
the drug; and an eriodictyon fluid extract.
The invention includes such formulations adapted for nasal administration.
[0060] In embodiments, the drug is selected from the group consisting of analgesics; opiates;
antibiotics;,anticholinergic agents; antidiabetic agents; antinauseants;
antineoplastic agents;
antipsychotics; steroids, therapeutic peptides; compositions far treating drug withdrawal;
psychopharmacological agents; peripheral nervous system drugs; drugs acting at synaptic or neuroeffector functional sites; smooth muscle active drugs; histamines and antihistamines;
anti-infective agents; cytostatics; antimalarials; aniiprotozoim agents.
[0061] In more particular embodiments, the drug is selected from the group consisting of analgesics; opiates; antinauseants; antipsychotics; compositions for treating drug withdrawal;
psychopharmacological agents; peripheral nervous system drugs; drugs acting at synaptic or neuroeffector functional sites; smooth muscle active drugs.
[0062]In other particular embodiments, the drug is selected i:rom the group consisting of antibiotics; antivirals; antimalarials; antiprotozoan agents.
[0063) The pharmaceutical compositions and systems of the invention can be used in different ways to accomplish somewhat different purposes. The drug delivery device described above is preferred for administering drugs to the olfactory nerve via an intranasal PATENT
administration route, and the eriodictyon fluid present in the excipient composition is useful in signifcantiy reducing local irritation or sensitization that so frequently occurs with this type of drug delivery. Furthermore, the eriodictyon fluid facilitates adherence of the drug to the mucosal tissue.
[0064] In an exemplary embodiment, at least 60% of the uptake of an administered dose of the drug is taken-up by the nervous system, rather than the vasculature route (i.e., direct delivery to the nervous system, rather than systemic delivery through the vasculature, leading up to the nervous system uptake). In a preferred embodiment, at Least 70% of the uptake of an administered dose of the drug is taken-up by the nervous system, rather than the vasculature route. In a more preferred embodiment, at least 80% of the uptake of an administered dose of the drug is taken-up by the nervous system, rather than the vasculature route. In an even more preferred embodiment, at least 90°~0 of the uptake of an adnunistered dose of the drug is taken-up by the nervous system, rather than the vasculature route. In the most preferred embodiment, at least 100% of the uptake of an administered dose of the drug is taken-up by the nervous system, rather than the vasculature route.
[0065] The materials, methods and devices of the present invention are further illustrated by the examples, which follow. 'these examples arc offered to illustrate, but not to limit the claimed invention.
EXAMPLES
[0066] A solution of oxymetazoline for nasal administration was prepared as summarized in the following table:
Components Quantity Water 90.0 wt.
Eriodictyon Fluid Extract 2.5 wt.
pH Buffer 1.5 wt.
Sodium Chloride 5.0 wt.
Oxymetazoline 1.0 wt.
[OOG7] The above composition is useful as a nasal spray. The composition may further include other active components as desired. The sodium chloride is added in an amount to PATENT
adjust to the saline composition of nornial nasal mucosal tissues, as is the pH of the composition.
[0068] A solution of amantadine for nasal administration to the olfactory nerve was prepared as summarized in the following table:
Components Quantity Water 90.0 wt.
Eriodictyon Fluid Extract 2.5 wt.
pH Buffer 1.5 wt.
Sodium Chloride 5.0 wt.
Amantadine 1.0 wt.
[0069] The solution is buffered as described in the preceding example.
[0070] A formulation of eriodictyon fluid extract was prepared as summarized in the following table:
Components Quantity 8xcipient (carrier) 1.0-99 wt.
Yerba Santa Fluid Extract* 99-1.0 wt.
Other Components 0-9.0 wt.
~ lJried eriodictyon can be obtained from Meer Corporation, North Bergen, New Jersey. It can be used to prepare the fluid extract in a manner substantially as described in Remington's Pharmaceutical Sciences, 17th Ed., cited supra, on pages 1286 and 1516. After preparation of the extract, the above ingredients can be mixed to give a formulation of Yerba Santa extract.
[0071] It is understood that the examples and embodiments described herein are for illustrative purposes only and that various modifications or changes in light thereof will be PATENT
suggested to persons skilled in the art and are to be included within the spirit and purview of this application and scope of the appended claims. All pulblications, patents, and patent applications cited herein are hereby incorporated by reference in their entirety for all purposes.
Claims (23)
1. A pharmaceutical formulation for delivery by nasal administration of a drug for the treatment of a disorder of the central nervous system to a mammalian nervous system, comprising:
the drug; and an eriodictyon fluid extract.
the drug; and an eriodictyon fluid extract.
2. The formulation of claim 1 wherein the drug is selected from the group consisting of analgesics; opiates; antibiotics; anticholinergic agents;
antidiabetic agents;
antinauseants; antineoplastic agents; antipsychotics; steroids, therapeutic peptides;
compositions for treating drug withdrawal; psychopharmacological agents;
peripheral nervous system drugs; drugs acting. at synaptic or neuroeffector junctional sites; smooth muscle active drugs; histamines and antihistamines; anti-infective agents;
cytostatics;
antimalarials; antiprotozoan agents
antidiabetic agents;
antinauseants; antineoplastic agents; antipsychotics; steroids, therapeutic peptides;
compositions for treating drug withdrawal; psychopharmacological agents;
peripheral nervous system drugs; drugs acting. at synaptic or neuroeffector junctional sites; smooth muscle active drugs; histamines and antihistamines; anti-infective agents;
cytostatics;
antimalarials; antiprotozoan agents
3. The formulation of claim 1 wherein the drug is not useful for treating a nasal or respiratory tract infection, for example is not an antiviral agent useful for treating such infections or a decongestant.
4. The formulation of claim 1 in combination with a pressurized delivery device, configured to deliver the drug and eriodictyon fluid extract to the olfactory nerve.
5. The use of an eriodictyon fluid extract for the manufacture of a medicament containing the eriodictyon fluid extract as an excipient or courier and for the treatment of a disease of the central nervous system or brain.
6. The use of an eriodictyon fluid extract for the manufacture of a medicament containing a drug and the eriodictyon fluid extract as an excipient or carrier, for transnasal-mucosal delivery of the drug to a component of the nervous system, which component is a member selected from the peripheral nervous system, the central nervous system and combinations thereof.
7. The use of claim 6 wherein the drug delivery essentially bypasses the vasculature.
8. The use of an eriodictyon fluid extract for the manufacture of a medicament for administration by olfactory pathway(s) and containing a drug as well as the eriodictyon fluid extract as an excipient or carrier, the medicament being for delivery of the drug to a site in the brain or central nervous system.
9. The use of any of claim 5, wherein the medicament further comprises a solvent selected from the group consisting of deionized water, and an aqueous-based solution and a non-aqueous solvent.
10. The use of any of claim 5, wherein the drug comprises an anti-oxidant.
11. The use of any of claim 5, wherein the drug comprises an anti-cancer chemotherapeutic.
12. The use of any of claim 5, wherein the medicament further comprises a vasodilator, in addition to said drug.
13. The use of any of claim 5, wherein the medicament is for delivery of the drug to a basal forebrain, a prepyriform complex, a hippocampal formation, an amygdaloid nuclei, a nucleus basalis of Meynert, a locus ceruleus, a brainstem raphe nuclei, or a combination thereof.
14. An apparatus to enhance delivery of at least one delivery substance into the central nervous system of a mammal, utilizing the olfactory pathway(s) as a direct delivery route for the substance from an exogeneous source via the mammal's olfactory area to a target site of the mammal's central nervous system, bypassing the mammal's blood brain barrier comprising:
(a) a drug;
(b) an excipient composition comprising eriodictyon fluid extract; and (c) a pressurized delivery device, configured to deliver the drug and excipient to the olfactory nerve.
(a) a drug;
(b) an excipient composition comprising eriodictyon fluid extract; and (c) a pressurized delivery device, configured to deliver the drug and excipient to the olfactory nerve.
15. A method of providing enhanced delivery of a drug to a mammalian nervous system, said method comprising:
administering said drug as a pharmaceutical composition with an eriodictyon fluid extract to a component of said nervous system, which is a member selected from the peripheral. nervous system, the central nervous system and combinations thereof, transnasal-mucosally, essentially bypassing vasculature, thereby providing said enhanced delivery of said drug.
administering said drug as a pharmaceutical composition with an eriodictyon fluid extract to a component of said nervous system, which is a member selected from the peripheral. nervous system, the central nervous system and combinations thereof, transnasal-mucosally, essentially bypassing vasculature, thereby providing said enhanced delivery of said drug.
16. The method of claim 15, wherein said drug further comprises a solvent selected from the group consisting of deionized water, and an aqueous-based solution and a non-aqueous solvent.
17. The method of claim 15, wherein said drug comprises an anti-oxidant.
18. The method of claim 15, wherein said drug comprises an anti-cancer chemotherapeutic.
19. The method of claim 15, wherein said drug further comprises a vasodilator.
20. The method of claim 15, wherein the drug is absorbed into the olfactory system.
21. The method of claim 20, wherein a fibroblast growth factor is transported through a peripheral olfactory nerve into an olfactory bulb.
22. The method of claim 20, wherein said drug is transported to a basal forebrain, a prepyriform complex, a hippocampal formation, an amygdaloid nuclei, a nucleus basalis of Meynert, a locus ceruleus, a brainstem raphe nuclei, or a combination thereof.
23
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA 2560798 CA2560798A1 (en) | 2005-09-26 | 2006-09-26 | Administering pharmaceutical compositions to the mammalian central nervous system |
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US72079705P | 2005-09-26 | 2005-09-26 | |
| US60/720,797 | 2005-09-26 | ||
| US11/460,194 US20070189976A1 (en) | 2005-09-26 | 2006-07-26 | Administering pharmaceutical compositions to the mammalian central nervous system |
| US11/460,194 | 2006-07-26 | ||
| CA2,556,010 | 2006-08-10 | ||
| CA002556010A CA2556010A1 (en) | 2005-09-26 | 2006-08-10 | Administering pharmaceutical compositions to the mammalian central nervous system |
| US11/527,900 | 2006-09-26 | ||
| CA 2560798 CA2560798A1 (en) | 2005-09-26 | 2006-09-26 | Administering pharmaceutical compositions to the mammalian central nervous system |
| US11/527,900 US20070071835A1 (en) | 2005-09-26 | 2006-09-26 | Administering pharmaceutical compositions to the mammalian central nervous system |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2560798A1 true CA2560798A1 (en) | 2007-03-26 |
Family
ID=37904953
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA 2560798 Abandoned CA2560798A1 (en) | 2005-09-26 | 2006-09-26 | Administering pharmaceutical compositions to the mammalian central nervous system |
Country Status (1)
| Country | Link |
|---|---|
| CA (1) | CA2560798A1 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020079258A1 (en) | 2018-10-19 | 2020-04-23 | Humabs Biomed Sa | Antibodies and methods for treatment of lyssavirus infection |
-
2006
- 2006-09-26 CA CA 2560798 patent/CA2560798A1/en not_active Abandoned
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020079258A1 (en) | 2018-10-19 | 2020-04-23 | Humabs Biomed Sa | Antibodies and methods for treatment of lyssavirus infection |
| WO2020078568A1 (en) | 2018-10-19 | 2020-04-23 | Humabs Biomed Sa | Antibodies and methods for treatment of lyssavirus infection |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP3511074B2 (en) | Pharmaceutical prescription for treatment of nicotine dependence | |
| US7033998B2 (en) | Alcohol-free transdermal insulin composition and processes for manufacture and use thereof | |
| Sears | Regulation of aqueous flow by the adenylate cyclase receptor complex in the ciliary epithelium | |
| ES2216279T3 (en) | USE OF MISOPROSTOL AND / OR MISOPROSTOL ACID FOR THE TREATMENT OF ERECTILE DYSFUNCTION. | |
| HU225963B1 (en) | Process for producing pharmaceutical compositions for the treatment of basal cell carcinoma and actinic keratoses | |
| US7291591B2 (en) | Alcohol-free transdermal insulin composition | |
| US20030157185A1 (en) | Topical treatment of neuropathy | |
| JP2021038250A5 (en) | ||
| US7871647B1 (en) | Topical treatment of neuropathy | |
| KR20070104912A (en) | Solid ophthalmic drug for external use | |
| CN1997383B (en) | Aequorin-containing compositions and methods of using same | |
| Haass et al. | Cardiovascular effects of calcitonin gene-related peptide in the pithed rat: comparison with substance P | |
| CN111195230B (en) | Method for preparing flexible liposome | |
| US20080176913A1 (en) | Transdermal compositions of pramipexole having enhanced permeation properties | |
| US6623732B1 (en) | Pharmaceutical formulation for nasal administration | |
| CA2560798A1 (en) | Administering pharmaceutical compositions to the mammalian central nervous system | |
| US20070071835A1 (en) | Administering pharmaceutical compositions to the mammalian central nervous system | |
| DE602005005454T2 (en) | Treatment of inclusion body myositis | |
| JP6162152B2 (en) | Transdermal administration of prostaglandin E1 to treat ocular ischemia | |
| Ayre | New approaches to the delivery of drugs to the brain | |
| Gallo et al. | Pump delivery of azidothymidine: potential for constant concentrations and improved brain delivery | |
| CN105381469A (en) | Medicine preparation for treating brain diseases | |
| CN110193078A (en) | One group of pharmaceutical composition and its carrier and dosage form for Cobratoxin intranasal administration | |
| EP1530455B1 (en) | A pharmaceutical formulation and its use in the treatment of inner ear diseases | |
| NZ281304A (en) | Nail coatings as systemic drug delivery systems |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Dead |